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Abstract 
 
The removal of an eye is one of the most difficult and dramatic decisions that a surgeon must 
consider in case of severe trauma or life-threatening diseases to the patient. The philosophy behind 
the design of orbital implants has significantly evolved over the last 60 years, and the use of ever 
more appropriate biomaterials has successfully reduced the complication rate and improved the 
patient’s clinical outcomes and satisfaction. This review provides a comprehensive picture of the 
main advances that have been made in the development of innovative biomaterials for orbital 
implants and ocular prostheses. Specifically, the advantages, limitations and performance of the 
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existing devices are examined and critically compared, and the potential of new, smart and suitable 
biomaterials are described and discussed in detail to outline a forecast for future research directions. 
 
Keywords: Orbital implant; Ocular prosthesis; Enucleation; Porous biomaterials; Antibacterial 
properties. 
 
1. Introduction 
 
Dating back thousands of years, there is evidence that the Sumerians and Egyptians were able to 
surgically remove the ocular globe as well as to make artificial eyes; however, it was not until the 
late 1500s that enucleation procedures were reported in detail in the medical literature [1]. The 
advances in this field progressed relatively slowly and only in 1885 the use of a well-defined orbital 
implant, a glass sphere, to restore the socket volume was documented [2]. Improvements in surgical 
techniques, anesthesia, implant materials and design over the last decades have significantly got 
better clinical outcomes and patient’s satisfaction. Furthermore, the ability to more effectively deal 
with the long-term complications of the anophthalmic socket such as enophthalmos, exposure and 
lower lid laxity (ectropion) have greatly improved. Today, most patients can confidently return to 
their daily activities with good cosmetic results following the removal of an eye. 
This article chronicles the evolution of orbital implants and ocular prostheses, gives a 
comprehensive overview of the current state of the art and provides a picture for prospective 
research. Other devices used in oculo-orbital surgery, such as the biomaterials for orbital floor 
repair, have been recently reviewed elsewhere [3-5] and are not included in the present work. 
Medical details are often given, so that the reader can well understand the key problems related to 
the use and applications of the described devices, the suitability and limitations of existing solutions 
and the potential of some novel approaches suggested at the end of the article. Just to give the 
reader a “road map” showing the organization of the article, it can be divided into three parts, 
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devoted to presenting an essential medical background, a comprehensive materials/implants review 
and some indications for prospective research and future challenges, respectively. The first part, 
section 2, gives the reader a concise overview of the surgical approaches that can be adopted to 
remove a diseased eye, as well as the basic information related to orbital implants and ocular 
prostheses. In this context Table 1 provides a short glossary of the medical terms that are not 
explained directly in the text which may be unclear or unknown to non-specialist readers. In the 
second part, the different types of biomaterials and devices used as orbital implants (section 3) and 
ocular prostheses (section 4) are extensively reviewed. At the end of the section 3, an organized and 
critical comparison among the several existing types of orbital implants is provided. The third part, 
Section 5, presents the future challenges in the field and particularly highlights the potential of new 
experimental biomaterials with advanced properties (e.g. angiogenetic ability, controlled resorption, 
antiseptic functionality). 
 
2. Need for eye removal: aetiology and surgery 
 
The removal of an eye or the orbital contents is one of the most serious and difficult decisions that a 
patient and a surgeon must consider. The patient facing the loss of an eye has often underwent 
multiple ophthalmic/orbital surgeries, experienced severe ocular trauma or been diagnosed with a 
potentially life-threatening disease, such as eye tissue tumours. Therefore, psychological support 
before and after surgery is fundamental in these patents, who are often feeling depressed and 
overwhelmed [6].  
At present, removal of a diseased eye can be carried out by following different surgical approaches, 
according to the particular pathology and medical history of each patient. Evisceration involves the 
removal of the intraocular contents of the eye while the sclera, Tenon’s capsule, conjunctiva, 
extraocular muscles and the optic nerve are left intact [7]. Enucleation is another option involving 
the removal of the globe from the orbital socket together with the scleral envelope and a portion of 
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the optic nerve, while, as with evisceration, the conjunctiva, Tenon’s capsule and extraocular 
muscles are spared [8,9]. It has long been believed that evisceration is superior to enucleation as to 
motility and cosmesis; however, modern enucleation procedures, which involves a careful 
attachment of extraocular muscles to the implant, actually rival those of evisceration in the 
preservation of motility of the artificial eye and cosmetic outcome. In the final stage of surgery, an 
orbital implant is placed within the scleral envelope after evisceration or within the Tenon’s capsule 
after enucleation; an ocular prosthesis will be then worn by the patient to restore an appropriate 
aesthetic appearance (Fig. 1). Unfortunately, recovery of the visual function of the eye by 
implantation of what we might ideally term “seeing artificial device” still remains a dream; 
nonetheless, the present surgical strategies are fully able to restore an acceptable cosmetic 
appearance and life-like motility to the prosthetic eye.     
Removal of an eye can be necessary in case of intraocular malignancy (e.g. retinoblastoma, which 
can develop especially in children), blind painful eye, prevention of sympathetic ophthalmia in a 
blind (or even seeing) eye, severe trauma, cosmesis and infections not responsive to pharmaceutical 
therapy. In some cases either approach can be adopted: from a general viewpoint, evisceration is 
less invasive and less surgically complex than enucleation and can be performed even under local 
anesthesia, but some reports demonstrated that the complication rate for evisceration, specifically 
implant extrusion, may be significantly higher [10]. Evisceration is indicated in the treatment of 
active, uncontrolled endophthalmitis and in all cases when there may be a danger of intraocular 
infection spreading back along a cut optic nerve sheath; however, enucleation may be indicated if 
the infection has spread to the sclera. Evisceration is also recommended in patients who cannot 
tolerate general anesthesia or have bleeding disorders since it is a faster, easier procedure and 
damages fewer blood vessels than enucleation. Evisceration is absolutely contraindicated in the 
presence of intraocular malignancy as it does not allow for eradication of tumour cells that have 
spread to the sclera. Enucleation is generally indicated for tumours that are confined to the ocular 
globe; exenteration procedure, which involves the removal of the entire orbit and surrounding 
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structures and tissues, should be performed if the malignancy has spread to the extraocular tissues 
and structures (e.g. adjacent sinuses, cranium bone, face muscles and skin, conjunctiva and eyelids) 
[11]. Exenterations vary in the amount of tissue removed and, apart from being indicated for the 
eradication of extended tumours, can be applied in the case of otherwise unmanageable rhino-
orbital infections and, less commonly, severe orbital pain and deformity [12]. After the socket has 
healed, silicone or acrylic custom-made prosthetic devices can be constructed and attached to the 
orbit or skin with various types of adhesives to provide an excellent cosmetic result [13]. The use of 
osteointegration techniques, which involve the permanent placement of bone-anchored titanium 
implants, can also be used to successfully support maxillofacial prosthetic devices [14]. 
 
3. Orbital implants 
  
Over the centuries, a wide variety of materials has been experimented to manufacture more or less 
rudimental orbital fillers with the aim of replacing the anophthalmic socket volume and restoring an 
acceptable aesthetic appearance to the patient’s face. Use of metals (e.g. gold, silver, platinum, 
stainless steel), substances of vegetal (e.g. wool) or animal (e.g. cork, ivory) origin and even rock-
derived materials (asbestos) has been documented [15]. Since the late 19th century, surgical 
procedures and materials to be implanted progressively moved to more defined standards, in order 
to avoid or at least to limit the negative outcomes of a “trial and error” approach. Therefore, the 
term “orbital implant” has been employed to denote a properly-designed, reproducible, often man-
made device which not only is able to replace orbital volume but also, hopefully, to ensure adequate 
motility to an aesthetic ocular prosthesis (artificial eye); in this review, particular emphasis will be 
dedicated to recently-developed solutions (approximately in the last two decades) and related 
studies. The earliest orbital implants were simple spheres buried within the Tenon’s capsule [2]; the 
extraocular muscles were disinserted from the globe and left to contract within the socket. Due to 
the limited movement of the overlying ocular prosthesis, surgeons began to perform the muscles 
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attachment to the implant to better anchor it, thereby reducing extrusion rates, and to allow 
conjugate movement with the contralateral normal eye.  
The attachment of the extraocular muscles to the implant, the implant incorporation within the 
surrounding orbital tissues and the implant-prosthesis interlocking have all become a source of 
some confusion in terminology over the years. For instance, some authors referred to “implant 
integration” as the simple attachment of the extraocular muscles to the implant, whereas other 
researchers defined integration as the mechanical contact between implant and ocular prosthesis. In 
order to solve this controversy, Sami et al. [15] recently suggested a 3-type categorization (buried, 
exposed-integrated and buried-integrated implants) based on the assumption that integration 
specifically refers to the nature of fit between the ocular prosthesis and the implant, whereas 
attachment of the extraocular muscles to the implant does not imply integration. In the present 
work, the authors propose a 7-type general classification of orbital implants (Table 2), in the 
attempt at taking in account all currently available implants, including the porous ones with their 
own peculiarities. According to this classification, some overlapping among the classes is 
unavoidable depending on the context of use; for instance, a solid silicone sphere may be a simple 
non-integrated device but, if wrapped within a foil of biological tissue, it will become a non-
integrated and biogenic implant. As the research continuously proceeds and new materials are 
developed, in the next future even a 8th class (bioactive implants) might be added to Table 2, as 
shortly discussed at the end of the article in the section 5.2.1.    
The orbital implants developed over the years – available on the marketplace or currently 
abandoned – are collected in Table 3 with essential information for the reader’s benefit. Just to 
provide a short overview of the complex issues related to the design and selection of suitable orbital 
implants, we have to mention that an ideal implant should display a number of characteristics, 
including biocompatibility, adequate volume replacement, adequate support for the ocular 
prosthesis, accessible cost for the patient, easiness of implantation, good motility transmitted to the 
ocular prosthesis and low rate of complications (e.g. post-operative infections). The use of non-
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toxic materials should be a mandatory pre-condition to produce biocompatible implants. In order to 
fit the anatomic needs of each specific patient, including children, implants of different size are 
today available on the marketplace; the prices are quite variable (from few tens to several hundreds 
Euros in Europe) and mainly depend on employed material and implant style. Surgical implantation 
can be facilitated by wrapping the implant within a foil of a smooth material; this procedure is 
particularly recommended for porous implants characterized by a slightly irregular porous surface. 
Over the years, different strategies have been developed to suture the extraocular muscles to the 
implant in order to improve motility; for instance, the muscle can be directly and independently 
attached to the implant or sutured together in front of it (imbrication). Different approaches were 
also experimented to improve the motility of the ocular prosthesis, including pegging procedures 
and use of magnets to guide the prosthesis movement in accordance to that of the orbital implant. 
Infections following implant exposure are more amenable to treatment in porous implants, as 
vascular in-growth helps to anchor the implant and permits immune surveillance. Therefore, the use 
of a porous implant is a good option in adults but is generally discouraged in children, since implant 
substitution with another one of larger size may be necessary to stimulate adequate orbital growth. 
All these issues will be critically discussed in the following sections to give the reader a 
comprehensive picture about features, advantages and limitations of each implant type as well as 
some criteria for implant choice.     
 
3.1. Non-integrated implants 
 
3.1.1. Glass 
 
In 1885, Mules placed the first orbital implant after evisceration [2] and one year later Frost 
described orbital implant placement after enucleation surgery [16,17]. The Mules implant was 
essentially a hollow blown glass sphere and commonly used till the World War II (WWII). Volume 
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replacement by the Mules implant within Tenon’s capsule was a significant advance, reducing 
socket retraction, intra-orbital fat redistribution and superior sulcus deformity. Implants of different 
sizes were experimented for better fitting to patient’s anatomy; it was also noted that the use of 
smaller and lighter devices led to decreased stress on the lower lid and associated ectropion 
formation. At the beginning, the Mules implant had high extrusion rates (50-90%), but the 
progressive improvement of surgical techniques led to the reduction in this complication, although 
still high compared to modern standards: Verrey reported an extrusion rate of 21% in 343 cases 
receiving the Mules implant up to 1898, and in 1944 Burch reported failures in less than 10% of 52 
operations [18,19]. The major drawbacks of Mules implant were the brittleness, as the implant 
could break due to trauma, and the risk of implosion due to sudden temperature changes.  
At present, use of glass spheres as orbital implants has been almost totally abandoned considering 
the availability of other implants generally ensuring better outcomes. Occasionally, glass has been 
still used in recent years: in the late 1980s Helms et al. [20] implanted a glass sphere (1 patient) that 
underwent posterior intracranial migration, and in the 1990s Christmas et al. [21] used a glass 
implant in a single patient without reporting any complication after a 2-year follow-up. 
 
3.1.2. Silicone  
 
Silicone has been extensively proposed for more than 50 years as a suitable material for various 
surgical applications due to its attractive properties, including biological/chemical inertness, 
flexibility, ease of handling and low cost. For instance, episcleral implants made of solid or porous 
silicone are still today the unique devices clinically approved and commercially available 
worldwide for scleral buckling in retinal detachment surgery [22]. 
As to orbital implants, a non-porous silicone sphere, as-such (bare) or wrapped, centered within the 
muscle cone and attached to the four rectus muscles has been the most common alternative to Allen 
and Universal implants before porous implants have been introduced on the market at the end of 
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1980s. The use of a non-porous silicone sphere is still now a good option if pegging is discouraged 
or cannot be performed; however, although prosthetic movement occurs, it is not as much as is seen 
with mounded (i.e. quasi-integrated) devices or pegged porous implants. In the view of many 
surgeons, a standard silicone sphere simply placed into the orbit, without a wrap and without 
connection to the rectus muscles, is the least desirable choice as it offers little movement and the 
implant is prone to migrate with time [23].  
Non-porous silicone spheres can be also preferred depending on the patient’s age. In infants and 
preschool-aged children, a wrapped silicone sphere centered within the muscle cone and connected 
to the four rectus muscles and inferior oblique muscle is often recommended; implant exchange 
with a porous orbital implant that may potentially be pegged is considered at a later age (> 15 
years). Some surgeons also prefer to implant a wrapped non-porous silicone sphere in aging patients 
(> 65 years); porous implants are not used routinely in this age group, as experience suggested that 
these patients are often bad candidates for pegging due to gradually failing health and difficulty in 
maintaining regular follow-up visits [23]. 
Excellent outcomes have been reported by suturing the recti independently to a 20-mm spherical 
silicone implant reinforced with autogenous fascia or preserved sclera: an extrusion rate of only 
0.84% (1 of 119 patients over a 10-year follow-up period) and no cases of implant migration were 
reported [24]. This is an interesting achievements as, when muscles are imbricated over the surface 
of a spherical implant, implant migration normally occurs more frequently with non-porous 
implants [25,26]. 
Many surgeons experienced that this implant is an excellent choice also in cases of trauma, such as 
a severe gunshot wound to the orbit, where extraocular muscles are unidentifiable and will not be 
reattached to the implant. The implant, usually wrapped within a sclera foil or other suitable 
biomaterial, can be placed into the orbit and the Tenon’s capsule and conjunctiva sewn over the top. 
Gonzalez-Candial et al. showed that, if pegging is not planned, no advantage seems to occur, in 
terms of motility, in using porous orbital implants instead of solid silicone spheres [27]. Christmas 
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et al. [21] performed six implantation, by using solid silicone spheres, without reporting any 
complications over a 2-year follow-up. Pegging procedures were sometimes performed also in 
presence of solid silicone implants; interestingly, Shoamanesh et al. [28] showed that silicone 
implants had significantly less pre-pegging and post-pegging complications (especially pyogenic 
granuloma and hypo-ophthalmos) than the other implant types (including the porous ones), which 
demonstrates the great potential – often underestimated after the introduction of porous implants – 
that silicone can still have today. 
Apart from solid spherical implants, for sake of completeness it is also worth mentioning the 
silicone-based orbital implant proposed in the late 1960s by Soll, who devised an inflatable silicone 
implant filled with silicone gel [29,30]. By using a 30-gauge needle, saline or antibiotic solution 
could be injected centrally through a self-sealing area; this implant was designed to preferentially 
expand superiorly in order to address superior sulcus deficit. Due to pressure-related problems 
occurring both intraoperatively and after implantation, associated to the risk of silicone gel release, 
this approach was abandoned. 
Silicone has also been recently proposed in the USA in the manufacturing of the commercially-
termed “Flexiglass system”, comprising a silicone ocular prosthesis together with some accessories 
(more information will be presented in the section 4.2) and an orbital device called “Flexiglass 
eye”. To the best of the authors’ knowledge, no clinical studies about the “Flexiglass eye” have 
been reported in the medical and scientific literature up to now; the few available information have 
been found on the producer’s website [31], wherein we simply read that clinical trials started in 
2005 and are currently on going. We textually report the sentences describing this product [31]: 
“With the use of a safe, topical ‘growing’ oil application, the Flexiglass™ eye can actually be made 
to expand to fill the pediatric patient’s eye socket. Therefore, one can quickly see that the 
advantages of having an eye growing with the pediatric patient are quite significant. When an ocular 
prosthesis inadequately compensates for the space of an eye socket, the socket will inevitably 
contract and deform resulting in an unsatisfactory cosmesis. This inadequate cosmesis can continue 
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into adulthood and possibly requires many grueling and unnecessary surgeries to properly correct”. 
The features of the described device are unclear and the authors have strong perplexities about the 
use of a ‘growing oil’ that allows the implant to fit the anophtalmic socket. Clarification of these 
crucial issues, which should involve an accurate, serious investigation of the actual suitability of 
this implant for clinical use and a careful monitoring of its current commercialization, is therefore 
strongly expected in the next future. 
 
3.1.3. Poly(methylmethacrylate) 
 
Poly(methylmethacrylate) (PMMA) is well-known in ophthalmology mainly as an ideal material to 
fabricate intra-ocular lenses [32], as well as rigid and semi-rigid contact lenses [33], due to its 
excellent biocompatibility with ocular tissues and transparency to visible light; furthermore, PMMA 
has been also widely used in oculoplasty. As to the field of non-integrated orbital implants, in 1976 
Frueh and Felker first described the use of the so-called “baseball implant”, i.e. a PMMA sphere in 
an envelope of donor sclera [34]; although originally described as a secondary implant, its design 
might allow primary implantation as well.  
In 1985, Tyers and Collin implanted 35 secondary and 6 primary baseball implants and monitored 
the patients over a 24-month follow-up [35]; complications occurred in 59% of cases, but most of 
them (e.g. postoperative oedema) were resolved by pharmaceutical treatment. Volume correction 
was excellent and the motility was apparently comparable with that of quasi-integrated implants; 
therefore, the authors concluded that the baseball implant had a promising potential and might be 
recommended both as a safe and convenient secondary implant and as the first approach to a 
volume deficit in the anophthalmic socket, but it should be avoided if the conjunctival fornices were 
already shallow as a result of previous surgery. On the other hand, they acknowledged that the 
reported series of primary baseball implants was too small to allow them to draw definite 
conclusions, and the use of this implant after recent trauma was discouraged. 
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In 1994, Leatherbarrow et al. [36] reviewed 44 patients receiving the baseball implant and reported 
6 cases of severe complications (1 case of unacceptable pain, 3 cases of implant migration and 2 
cases of implant exposure). In the late 1990s, Christmas et al. [21] implanted the baseball implant in 
6 patients (primary enucleation) and implant removal was necessary in one case (exposure after 14 
days).  
Some interesting studies have been recently performed in Pakistan using the so-called Sahaf 
implants, made of solid PMMA. The development of a new, cost-effective implant that could be 
readily available on site was an urgent need for Pakistani ophthalmic surgeons as the most 
commonly used porous orbital implants have to be imported from abroad through a process that can 
take several weeks. From 2003 to 2006 Kamal-Siddiqi et al. [37] implanted in 60 enucleated 
patients the Sahaf implant type I, that was characterized by a 2-piece design wherein the posterior 
hemispherical portion gave support to hold recti muscles and the anterior convex curvature 
supported the ocular prosthesis; it was also available with multiple sizes to restore different ocular 
volumes. The anterior part of the implant was wrapped in sclera or fascia lata in some cases. After 
surgery, three initial cases showed necrosis of the conjunctiva leading to exposure of the implant, 
which needed reinforcement by autogenous fascia lata, and in one case the anterior part of the 
implant was extruded; in general, all cases had satisfactory socket filling. These early results were 
promising but the authors wisely concluded that further studies and long-term follow-up on a 
broader number of cases were needed to draw definite conclusions about the advantages of Sahaf 
orbital implant I over the existing ones. 
Kamal et al. [38] also reported a review of 30 patients who received, from 2006 to 2009, a pear-
shaped PMMA non-integrated implant (the so-called Sahaf orbital implant type II) which rested on 
the orbital floor and projected up to fill the orbit (Fig. 2a). Most of patients underwent enucleation, 
but this implant was also used in some cases of exenterated socket, along with temporalis muscle 
rotation and with 360° fornix reconstruction using mucous membrane graft. Wrapping of donor 
sclera or autogenous fascia lata was used in most cases. Postoperatively, two cases exhibited initial 
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necrosis of the conjunctiva leading to exposure of implant, which needed reinforcement by 
autogenous fascia lata.   
Among the recently-developed designs, it is worth mentioning the clever approach reported by 
Agahan and Tan [39], who hypothesized that implant weight might be a cause for most cases of 
implant migration; hence, they suggested that a hollow PMMA implant would be expected to be 
more stable compared with a solid implant of the same size as it would be subjected to less 
gravitational force. Hollow implants were manufactured by fusing 2 hemispherical elements made 
from medical-grade PMMA powder. Twelve patients were randomly divided into two equal groups, 
receiving either the standard solid acrylic implant or the hollow PMMA implant, respectively. The 
anophthalmic socket was examined postoperatively by serial computed tomography (CT) scanning 
to detect implant migration. Most of the implants remained in the socket at least 6 weeks in both 
groups, with 1 case of early implant extrusion in the solid acrylic group. Small degree of implant 
migration was observed on CT scans in 4 patients in the solid acrylic group and 3 in the hollow 
PMMA group after a 12-week follow-up. In the solid acrylic group, the implant migrated 
posteriorly in eviscerated patients and anteriorly in enucleated patients. No pattern was observed in 
the type of operation and direction of the implant migration in the hollow PMMA group. The 
authors concluded that hollow PMMA implants were comparable substitutes for solid acrylic 
implant, but multicenter clinical trials with adequate patients’ sample size and longer follow-up are 
needed to establish the long-term stability of the implant. 
In summary, PMMA is an excellent biomaterial for ophthalmic applications; it is also commonly 
used to manufacture ocular prostheses (as described in the section 4) and has been recently 
proposed for the repair of extensive orbito-facial defects due to trauma. In an interesting study, 
Groth et al. [40] treated 9 severely-injured patients by implanting CT-based biomodelled, 
prefabricated, heat-cured PMMA implants, that were well tolerated postoperatively; further 
advantages included customized design, long-term biocompatibility and excellent aesthetic results. 
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The criteria adopted for the choice of a PMMA non-integrated spherical implant are substantially 
analogous to those that were already presented for the silicone sphere; for instance, many surgeons 
prefer to implant a PMMA non-porous sphere (or a silicone one, that is slightly more pliable) rather 
than a porous device in children and elderly patients [23]. PMMA has been also used for 
manufacturing the majority of quasi-integrated implants, that are described in the section 3.2. 
 
3.2. Quasi-integrated implants 
 
An interesting approach to provide adequate motility without interrupting the conjunctival lining, 
with the aim of minimizing discharge and infections related to exposures or pegging procedures, 
was introduced about 70 years ago with the use of what is known as a quasi-integrated orbital 
implant design. These implants have irregularly-shaped anterior surfaces that create an indirect 
coupling mechanism between implant and ocular prosthesis, thereby allowing movement transfer 
from the implant to the artificial eye and, accordingly, imparting greater mobility to the latter one. 
The posterior surface of the ocular prosthesis is modified so that it fits in a “lock-and-key” fashion 
with the anterior surface of the implant, although it remains buried beneath the conjunctiva. Among 
the various types of orbital implants, the quasi-integrated ones nicely capture the progression of 
orbital implant design and “philosophy” from the WWII to present. 
 
3.2.1. Early models 
 
In 1946, Cutler introduced the so-called “basket implant” (Cutler implant I), that had four openings 
through which the rectus muscles were pulled through and sutured together with the patient’s 
conjunctiva closed over it; the ocular prosthesis had a knob on its posterior surface that fitted into 
the concavity of the (female) implant without direct contact [41]. Some variations of the quasi-
integrated Cutler implant have been proposed in the following years, such as the King implant that 
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consisted of a pear-shaped tantalum mesh at whose base the rectus muscles were attached with the 
patient’s conjunctiva closed over it [17]. The interested reader can find a comprehensive historical 
picture about early quasi-integrated models in a valuable paper by Gougelmann [17].  
 
3.2.2. The Allen implant and its evolutions 
 
The original Allen implant, that was developed in the mid 1940s by Prof. James Allen (Iowa 
University) together with the ocularist Lee Allen, was actually a mechanically-integrated PMMA 
implant connected by a thin rod (peg) to the aesthetic ocular prosthesis [42]. In the attempt of 
improving the design of Cutler integrated (female) implant (section 3.4), the Allen design 
incorporated the peg into the implant (male); each rectus muscle was passed through a peripheral 
tunnel, split lengthwise to straddle the gold peg and was sutured to its antagonist. Unfortunately, 
this first model gave less than satisfactory results as these implants were retained only a few months 
before they extruded or were removed because of infection due to bacterial colonization of 
implant/tissues [43]. The implant design was therefore modified: the peg was removed, the muscles 
were sutured together (or “imbricated”) through a central 6-mm opening and the Tenon’s capsule 
and conjunctiva were completely closed over the flat PMMA surface of the implant that was thus 
buried beneath the tissues of the eye socket. Such a design for the Allen implant was widely used 
for more than 10 years until it was replaced by a modified version developed to address the 
common complaints of some of the ocularists who were fitting them. For instance, since the flat 
surface did not well support the weight of the ocular prosthesis against gravity, lower lid droop and 
exaggeration of the upper lid sulcus were noticeable in some patients [44]. In the late 1970s Jahrling 
[45] reported an average 19% incidence of exposure among 186 Allen implants; in other long-term 
studies, however, much lower exposure rates (about 1%) were found and no exposure occurred 
before 5 years of follow-up [44]. 
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For the redesign, Lee Allen saw the advantage of a differently-shaped motility implant with 
pronounced irregularity on its anterior surface, in order to connect it more securely to the artificial 
eye’s posterior surface, which was shaped to match the irregular anterior surface of the implant. 
This next design, first reported in 1959, was referred to as the quasi-integrated Iowa implant I [46]; 
the Iowa implant II, introduced one year later, was similar in shape but nearly one third larger in 
volume [47]. The Iowa implants (type I and II), made of PMMA, had four peripheral mounds 
(height 5 mm) on the anterior surface designed to integrate with four depressions on the back of the 
ocular prosthesis (Fig. 2b); the rectus muscles were brought together through the valleys between 
the mounds, overlapped and tied together at a central anterior depression. Holes were also made 
through parts of the implant in the attempt at promoting fibrovascular tissue in-growth – this 
concept will be fully explored and applied 25 years later with the development of porous implants 
(section 3.5). The Iowa implants addressed many of the problems complained about the Allen 
implant: for instance, the four surface small hills supported the ocular prosthesis and remarkably 
reduced gravitational effect on the lower lid. Spivey et al. reported a 3.3% exposure rate of Iowa 
implants over a 10-year follow-up [48]. It was also noted that Iowa implants exposure was usually 
localized at the surface of the mounds due to pressure-induced necrosis; therefore, the Iowa 
implants design was modified and the Universal implant, exhibiting lower and more round-shaped 
mounds (Fig. 2b), was introduced in the late 1980s [49,50]. However, the Universal implant was 
not widely used because it emerged around the same time that the porous implants begin to greatly 
spread on the market. 
 
3.3. Magnetic implants  
 
The class of magnetic orbital implants deserves a particular mention. From a historical perspective, 
the development of orbital implant design seems to be mainly “evolutionary”, as surgeons and 
ocularists progressively tried to improve implant performances and clinical outcomes by 
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overcoming step-by-step some specific drawbacks which featured the implants proposed by their 
predecessors; a typical example is represented by the modifications of the Allen implant towards the 
Iowa and eventually the Universal implant. However, in the authors’ view, magnetic implants might 
be considered – at least partially – “revolutionary” due to the interesting principle behind their 
action. Essentially, the ocular prosthesis is held in place and the implant movement can be 
transferred to it by means of the action of magnets with opposite poles incorporated on the posterior 
surface of the prosthesis and within the anterior region of the implant, respectively; the conjunctiva 
is sandwiched between the two elements. 
This approach was introduced after the WWII and led to the development of a certain number of 
early models [51-56]. In 1954, Troutman [51] published the results of a 5-year follow-up including 
102 patients receiving a magnetic orbital implant and reported an extrusion rate below 4%. Roper-
Hall [55,56] developed a magnetic implant deriving from the Allen design and consisting of a 
PMMA 21-mm hemisphere with a flat anterior face into which a magnet was embedded; a ring of 
the same material stand forward of the face and had tunnels through which the 4 rectus muscles 
might be passed. More horizontal than vertical movement of the artificial eye was usually seen, and 
this could be increased in all directions if additional magnets were placed in the ocular prosthesis. 
Unlike the mechanically-integrated (pegged) implants developed in the same period, this implant 
did not have an extreme amplitude of movement, for it was limited to a “conversational” range [57]. 
In the early 1980s, Atkins and Roper-Hall [58] monitored 66 enucleated patients over a 5-year 
follow-up: only 1 case of extrusion was reported, together with residual problems of lower lid droop 
and a deep upper lid sulcus. 
Magnetic implants generally had adequate movement, but if the magnet was too strong or 
misaligned, conjunctiva and Tenon’s capsule tissue could become compressed between implant and 
prosthesis, thereby leading to breakdown and exposure along the outer edges [59]. These implants, 
although representing a clever approach to the problem of implant-prosthesis integration, exhibited 
two apparently unavoidable drawbacks. The first issue was recently pointed out by Sami et al. [15], 
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who clearly recognized local toxicity related to iron ions accumulation within the conjunctival 
tissues and associated tissue necrosis as an important cause of possible tissue breakdown and late 
exposure. Over time, PMMA tends to absorb water due to prolonged contact with biological fluids, 
which may cause magnet rusting (Fig. 2c,d) with subsequent exposures developing over the central 
anterior surface, as opposed to the peripheral edges which are prone to pressure necrosis [60]. The 
second issue is common to all metallic implants or prostheses that can be potentially hazardous 
during magnetic resonance (MR) imaging because of movement or dislodgment of the foreign 
metal object [61]. Yuh et al. [62] reported a case of a magnetic orbital implant extrusion caused by 
implant movement during MR imaging at 0.5 T. In recent years, there has been a renewed interest 
by surgeons, biomaterials researchers and implant producers towards magnetic orbital implants, as 
demonstrated by some relevant patents deposited in the early 2000s [63,64]. 
 
3.4. Mechanically-integrated implants 
 
The evolution of quasi-integrated and mechanically-integrated (pegged) orbital implants was 
substantially concurrent. In the late 1940s, Cutler described a PMMA “ball-and-ring” implant 
(Cutler implant type II) whose exposed face had a square (female) receptacle, into which a gold 
square (male) peg attached to the ocular prosthesis could be inserted; the rectus muscles were 
looped around and sutured to the ring [65,66]. In the following years, similar implants were 
developed by other researchers with slight modifications [15,17]. 
It is worth mentioning that pegged integrated implants were developed not only for enucleation but 
also for evisceration. In 1951, Young first described a PMMA implant to be inserted in an 
eviscerated globe; the device was maintained in position by tantalum wires passing through the 
sclera and the peg passed through a hole in the cornea, thereby acting as an obturator on which the 
ocular prosthesis rested [67].      
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All these implants generally gave excellent movement, but their long-term results were 
unsatisfactory. In a review of the outcomes of 91 patients receiving mechanically-integrated 
implants, Choyce found that the rate of survival after a 2-year follow-up was from 40 to 50% 
depending on the implant type; infection due to bacterial colonization of peg/tissues was the reason 
for extrusion and subsequent removal in 80% of cases [68]. For this reason, the use of 
mechanically-integrated implants was progressively abandoned and the adoption of quasi-integrated 
ones was preferred until the diffusion of porous implants widely took place about 20 years ago: the 
“peg approach” has been re-invented and applied to this new generation of implants that allowed 
better outcomes thanks to fibrovascular in-growth within the pores. 
 
3.5. Porous implants 
 
From the design style viewpoint, in some ways the porous orbital implants represented a sort of 
“regression”, since the porous sphere could not translate movement to the implant as the irregular 
anterior surface of quasi-integrated implants did. On the other hand, advantages of porous implants 
included fibrovascularization with intrinsic decrease of infection risk as well as the capability of a 
more effective treatment of infections via antibiotic systemic therapy. If porous implants are used 
for evisceration, scleral windows should be produced by the surgeon to allow fibrovascular in-
growth; the same approach is recommended if the implant is covered with wrapping material. Some 
examples of clinically-used porous orbital implants are collected in Fig. 3. The majority of scientific 
articles and books dealing with materials for ophthalmolplasty indicate the coralline hydroxyapatite 
(HA) implant, introduced in the mid 1980s, as the first example of porous orbital devices that have 
revolutionized anophthalmic socket surgery. However, this statement is only partially correct as 
porous orbital implants actually have an older but often forgotten history, as shortly summarized in 
the following two sections.  
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3.5.1. Bone-derived orbital implants 
 
More than one century ago, in the attempt at overcoming the complications related to the Mules’s 
glass implant, a wide variety of different materials were experimented, including the mineral matrix 
of bovine cancellous bone first introduced by Schmidt in 1899 [69]. This implant was prepared by 
heating spheres of cancellous bone to destroy all organic matter, leaving only the calcium phosphate 
mineral framework [70], that was subsequently shown to consist predominantly of ultramicroscopic 
crystals of HA with small amounts of calcium carbonate and calcium citrate [71,72]. Schmidt’s 
bone-derived HA spheres were used until 1930 [73] and a variation of this implant, i.e. the so-called 
Guist’s implant constituted by calcined bovine bone spheres [74,75], was widely used and 
recommended as “the most satisfactory of all orbital implants” before the WWII [76]. 
Since the 1950s, biologically-inert non-integrated polymeric spheres (silicone and PMMA) 
progressively displaced the early types of porous implants. In the 1960s, Molteno carefully 
reviewed the existing literature on orbital implants and noted that the earlier bone-derived HA 
implants had given good results and that small exposures of the implant during the postoperative 
period frequently healed spontaneously [76]. This behaviour, which was quite unlike that observed 
with a smooth surfaced polymeric implant, suggested that the biodegradable microcrystalline HA 
matrix of bone would constitute a superior orbital implant since, once organized by host connective 
tissue, it would not migrate through the tissues while any small exposures would heal 
spontaneously. Furthermore, the mass of host connective tissue incorporating the bone mineral 
implant would be likely persist unchanged for the patient’s whole life. The early trials of this type 
of implant (M-Sphere, Molteno Ophthalmic, New Zealand; currently it is also produced by IOP 
Inc., Costa Mesa, USA) were reported in the early 1970s and 1980s [77,78], involved the use of 
deproteinized (antigen-free) bone of calf fibulae and confirmed that the mineral matrix of 
cancellous bone was readily incorporated into the tissues and that small exposures were followed by 
spontaneous crumbling of the exposed bone with healing of the overlying conjunctiva. Other 52 
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cases with up to 10-year follow-up were reported in 1991 [79], and the long-term successful 
outcomes of 120 M-Sphere orbital implants inserted after enucleation between 1977 and 2000 were 
more recently documented [80]. This implant, however, is significantly more porous and, 
accordingly, more fragile than other available HA implants (described in the section 3.5.3) and may 
be unable to support a peg [81,82]. Furthermore, its comparatively high cost (500 € or more) may 
have contributed to its relatively limited diffusion.  
 
3.5.2. Proplast 
 
Unlike what commonly reported in most of the literature, the first porous orbital implant made of an 
artificial material was introduced more than one decade before synthetic HA and polyethylene (PE) 
porous implants. In the late 1970s, Lyall [83] pioneered the use of Proplast, an inert felt-like 
composite material constituted of polytetrafluoroethylene (Teflon) and carbon fibres, to 
manufacture hemispherical orbital implants (Proplast implant I) that, when implanted, could be 
invaded by fibrous tissue to overcome the problem of extrusion and rejection; no rejection was 
reported after a 18-month follow-up in 16 patients receiving such implants and the motility was 
generally good. Neuhaus et al. tested Proplast implants I in rabbits and observed a high degree of 
soft tissue fixation with no implant migration; subsequent human use showed good results in 4 
patients followed for 2 years and in 6 patients followed for 1 year, with no cases of extrusion or 
migration in both groups [84]. In recent years, however, the popularity of Proplast has declined 
because of long-term post-operative complications, primarily late infections, associated with its use 
[85]. 
 
3.5.3. Hydroxyapatite 
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Porous orbital implants spread worldwide after the introduction of modern HA orbital implants, that 
are not based on treated bone deriving from animal sources. HA formally belongs to the class of 
calcium orthophosphates and, especially in form of coralline or synthetic HA, has been widely used 
since more than 50 years in orthopaedics and dentistry for bone repair thanks to its chemical and 
compositional similarity to biological apatite of hard tissues; interested reader can find 
comprehensive pictures about the features and use of HA and calcium phosphates in medicine in a 
series of reviews published by Dorozhkin [86-88]. 
Perry experimentally introduced the coralline porous HA sphere (Bio-Eye® Orbital Implants or 
Integrated Orbital Implants, Inc., San Diego, CA, USA) (Fig. 3a) in the mid 1980s [89] and since 
the early 1990s it has been commonly adopted in the clinical practice, eventually becoming the 
most frequently used implant after primary enucleation [90]. Due to this reason, porous HA 
implants have been widely studied and a lot of retrospective reviews on patients’ outcomes are 
available in the literature [23]. The interconnected porous structure of the HA implant allowed host 
fibrovascular in-growth, which potentially reduces the risk of migration, extrusion and infection 
[91]. Apart from discouraging bacterial colonization of implant surface, vascularization also allows 
the treatment of ocular infection by antibiotic therapy. Extraocular muscles can be securely attached 
to the HA implant, which in turn leads to improved implant motility [89,92]. By drilling into the 
frontal region of the HA implant and placing a peg, that can be subsequently coupled to the 
posterior surface of the ocular prosthesis, a wide range of artificial eye movements (especially along 
the horizontal axis) as well as fine darting eye movements (commonly seen during close 
conversational speech) can be achieved, thereby imparting a more life-like quality to the artificial 
eye. 
Besides the above-mentioned advantages, however, coralline porous HA implants had – and still 
have – two peculiar drawbacks. The first problem is ecological, as the manufacture of such an 
implant involves damage to sea life ecosystems due to the harvesting of natural corals; the second 
issue is related to the significant raise of the costs associated with enucleation, evisceration and 
23 
 
more generally ophthalmoplastic surgical procedures. In fact, the expenses associated to the 
placement of coralline HA implant include the intrinsic cost of the implant (600 € or even more, 
whereas traditional silicone or PMMA spherical implants range within 20-50 €) – which is often the 
most significant cost –, the need for a wrapping material, the assessment of implant vascularization 
with a confirmatory magnetic resonance imaging (MRI) study and, even if optionally, a secondary 
drilling procedure for peg placement with the consequent modification of the ocular prosthesis. 
Mainly in order to reduce the cost of the device, other forms of HA have been proposed as suitable 
and less expensive materials for implant fabrication. Synthetic HA implants (FCI, Issy-Les-
Moulineaux, Cedex, France) [93], that are currently in their third generation (FCI3), have an 
identical chemical composition to that of the Bio-Eye®, although scanning electron microscopy 
(SEM) investigations revealed some architectural differences (lower porosity: 50 vs. 65 vol.%; 
decreased pore uniformity and interconnectivity; presence of blind pouches and closed pores) [94]. 
Central implant fibrovascularization in a rabbit model appeared to occur in both Bio-Eye® and FCI3 
implants [95]. FCI3 implant has gained increasing popularity over the past 10 years especially as it 
is significantly less expensive than the Bio-Eye® (approximately 450 € vs. 600 €) and easier to drill 
for peg placement. 
Lower-cost versions of these materials have been developed and are currently in use around the 
world; however, they exhibit some drawbacks that strongly limit the (economic) advantages over 
the other available models. The Chinese HA implant (H+Y Comprehensive Technologies, 
Philadelphia, USA) has been reported to contain some CaO impurities that, after hydration in host 
tissues, may form Ca(OH)2, which is caustic [96,97]. The Brazilian HA implant, currently available 
in Brazil only, has higher weight, lower porosity and lower pore interconnectivity than Bio-Eye® 
and FCI3 implants, with consequent enhanced risk of implant migration and limited 
fibrovascularization [98]. Other types of synthetic HA implants (75 vol.% porosity, pore sizes 
ranging from 100 to 300 µm) were also recently used in India leading to patient’s good outcomes 
[99].  
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Despite the relatively good overall biocompatibility profile, HA generally exhibits certain 
drawbacks for use in orbital implants. Being a porous ceramic, its brittle nature precludes suturing 
the extraocular muscles directly to the implant [8,9]. There are convincing evidences that the rough 
surface of HA implants may adversely impact on biocompatibility, contributing to the development 
of late exposure due to the abrasion of the relatively thin conjunctiva and Tenon’s capsule as the 
implant moves. Therefore, it is generally recommended that HA implants are placed within a 
wrapping material (Fig. 3d) before introduction into the orbit [100-102]. It was shown that the 
majority of exposed HA implants can be successfully treated by using patch grafts of different 
origin (e.g. scleral graft, dermis graft, oral mucosa graft) without the need for implant removal 
[103-105]. In case of orbital implant infections, administration of systemic antibiotics and topical 
eye drops can solve the problem, but if no symptoms improvement is noticed, implant removal 
should be considered [106].   
Other reported complications include conjunctival thinning (followed or not by exposure), socket 
discharge, pyogenic granuloma formation, mid-term to chronic infection of the implant and 
persistent pain or discomfort [107-111]. In order to solve the possible problem of peg extrusion 
from drilled HA implants due to hole occlusion, Lew et al. proposed a 0.5 mg ml-1 mitomycin-C 
application to the drill hole and obtained good results in an albino rabbit model [112]. 
The use of porous HA implants in pediatric population has been alternatively advocated and 
castigated – implant exchange should be necessary later since the patient is growing, but its removal 
is difficult due to fibrovascularization – and this controversy still lingers on [113,114]; at present, 
non-porous implants seem to remain the preferable choice in children for the majority of surgeons 
[23]. In summary, porous HA implants still remain the most commonly used in anophtahlmic 
surgery and their advantages and suitability, in regard to considering the patient’s overall life 
quality, have been recently underscored by Wang et al. in an interesting paper [115]. However, in 
the search for an “ideal” porous orbital implants with a reduced complication profile and diminished 
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surgical and postoperative costs, alternative materials have been also explored over the last two 
decades. 
 
3.5.4. Polyethylene 
 
Synthetic porous PE implants (Medpor®, Porex Surgical Inc., Newnan, USA) were introduced in 
the late 1980s for use in the orbit and have been widely accepted as an alternative to the Bio-Eye® 
HA [116,117]. Furthermore, since then Medpor® thin sheets have been also used for the surgical 
repair of orbital floor fractures [5].  
In an animal model study, Goldberg et al. suggested that porous PE induces less inflammation and 
fibrosis than HA [118]; similar conclusions were more recently reported by Jordan et al. [119]. 
SEM investigations showed that porous PE implants exhibit a smoother surface than coralline HA 
(Bio-Eye®), synthetic HA (FCI3) and even aluminum oxide implants [119,120]. PE implants are 
also malleable, which permits easier implantation and potentially less irritation of the overlying 
conjunctiva following placement in comparison to porous HA spheres. On the other hand, the rate 
of vascularization of porous PE appears to be slower than coralline HA (Bio-Eye®), synthetic HA 
(FCI3) and aluminum oxide implants [119] as well as dependent on the pore size: PE implants with 
400-µm pore size vascularize more rapidly than those having 200-µm pore size [118,121]. In a 
recent work by Choi et al., gadolinium-enhanced MRI showed that the rate of fibrovascularization 
was similar for enucleated and eviscerated eyes in rabbits [122]. 
Medpor® implants may be used with or without a wrapping material and the extraocular muscles 
can be sutured directly onto the implant, although most surgeons find this difficult without 
predrilled holes [123]. In a minipig model, acellular dermis wraps were observed to support 
fibrovascularization of porous PE (and HA) orbital implants without inducing significant 
inflammation and persisted in situ for at least 12 weeks after surgery [120]. A recent retrospective 
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report by Blaydon et al. suggested similar exposure rates for wrapped and unwrapped porous PE 
implants (< 5%) [117]. 
An unusual complication following implant exposure was reported by Robberecht et al., who 
described a patient with lost eyelashes perpendicular to the extruding part of a porous PE implant 
due to their entrapment within the implant pores [124]. Infections of porous PE implants are 
generally rare [125]. Chuo et al. carefully reviewed the histopathologic features of 18 explanted 
porous PE orbital implants and confirmed that anterior exposure is a risk factor allowing bacterial 
colonization; furthermore, poor tissue in-growth may limit the penetration of topical or systemic 
antibiotic therapy, leading to the need for implant removal [126]. 
Comparative studies about the postoperative problems associated to HA and PE implants did not 
provide yet definite conclusions. In 2008 Sadiq et al. analyzed 2 groups of 26 patients receiving a 
HA or porous PE implant, respectively, and reported that the complication rates were identical 
between the groups; only, the implant motility was better in the PE group [127]. On the contrary, 
Ramey et al. found that porous PE and aluminum oxide implants were associated with higher 
exposure rates and higher overall complication rates compared to HA implants [128]. It is worth 
mentioning that the type of material is certainly a key aspect but, in clinical practice, the choice of 
orbital implant is often mainly governed by other factors such as surgeon experience, ease of use 
and cost. Porous PE implants were also used in pediatric population with satisfactory outcomes and 
relatively low complications rates [129, 130]. Some authors have recently suggested that the risk of 
exposure can be prevented if the porous PE implant is used in combination with a free orbital fat 
graft over its anterior surface [131,132]; however, Kim et al. observed in a rabbit model that the fat 
patch on Medpor® implants was gradually resorbed and the fat-occupied volume was not 
maintained [133]. 
The first generation of spherical porous PE implants had a rough surface like HA – probably this 
was the reason why a high exposure rate (about 22%) was reported in the early studies [134] – and 
quite homogeneous pore distribution [123]; since then, implants with gradients of porosity have 
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been introduced. For instance, the smooth surface tunnel sphere (SSTTM, Porex Surgical Inc., 
Newnan, USA) has suture tunnels for easier muscle attachment and exhibits a non-porous anterior 
surface to prevent abrasion of the overlying tissue while retains a larger pore size posteriorly to 
facilitate fibrovascular in-growth [135]. Other currently available Medpor® implants (Fig. 3b) 
include some variations of the standard porous sphere (e.g. egg-shaped implant developed for easier 
implantation), conical implants with a flat anterior surface and an upward projection to reduce 
superior sulcus defect [136] and the recent quasi-integrated “quad” PE motility implant (Medpor 
QuadTM Motility Implant, Porex Surgical Inc., Newnan, USA), which is similar in design 
philosophy, shape and method of muscle attachment (imbrication) to the Iowa and Universal 
implants (see the section 3.6). A standard spherical Medpor® implant costs approximately 150 € 
less than the Bio-Eye® porous HA sphere; new-generation PE implants having complex shape and 
advanced functionalities are more expensive proportionally. 
By looking at the future of PE orbital implants, it is instructive to mention the recent work by 
Kozakiewicz et al. [137] who fabricated by a CAD-CAM approach and implanted in 3 patients 
ultra-high molecular weight PE implants for orbital reconstructions. On the basis of CT scanning, 
the authors prepared a virtual model of both orbits (injured and uninjured); the two resulting 
surfaces were then overlapped and the outer surface, taken from the injured orbit, was used to 
design the external surface of the implant whereas the inner profile, taken from the uninjured orbit, 
was followed for the internal surface of the implant. This new, advanced approach could be applied 
in the future also for designing and manufacturing orbital implants closely mimicking the original 
shape and size of the anophtalmic socket; issues to be considered concerns the long time required to 
design and manufacture implants at the pre-operative stage and, accordingly, their high cost. 
 
3.5.5. Polytetrafluoroethylene 
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The use of expanded (porous) polytetrafluoroethylene (ePTFE or Gore-Tex; W. L. Gore & 
Associates, Flagstaff, USA) spheres as orbital implants was investigated by Dei Cas et al. in the late 
1990s [138]. The left eyes of 6 New Zealand white rabbits were enucleated and replaced with 
spherical Gore-Tex implants. After a 6-week follow-up, no rabbits developed a postoperative 
infection and no cases of exposure or extrusion were noted; there was also evidence of 
inflammatory infiltration and fibrovascular in-growth into each implant to a maximum penetration 
depth of 500 µm. Histopathologic analyses revealed varying degrees of acute and chronic 
inflammation surrounding each implant; probably, this is the reason why no other studies on Gore-
Tex as an orbital implant biomaterial were carried out in the following year.  
It is instructive to mention that, in the ophthalmic field, the problems related to ePTFE-induced 
inflammatory reactions were also found by Mourtemousque and associates [139,140], who 
investigated its use as a scleral buckling biomaterial for the treatment of retinal detachment; 
stiffness mismatch with orbital tissues is probably one of the reasons why these postoperative 
complications occurred.  
 
3.5.6. Aluminum oxide 
 
Aluminum oxide (Al2O3), commonly termed alumina, has been used for decades in orthopaedics 
thanks to its attractive mechanical properties (high hardness and compressive strength, excellent 
resistance to wear), biocompatibility and bio-inertness. For instance, the introduction of alumina 
and, later, alumina-based ceramic composites for manufacturing prosthetic femur heads had a 
significant impact in the field of hip joint replacement, leading to an improvement of prosthesis 
duration and performance as well as of patient’s life quality [141]. Since the late 1990s, alumina 
was also proposed in a porous form to fabricate orbital implants to be used in ophthalmoplasty; this 
type of device was approved by US Food and Drug Administration in April 2000 and has been 
marketed under the commercial name of “Bioceramic implant” (Fig. 3c). 
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The first in vivo study was reported in 1998 by Morel et al. [142], who evaluated the clinical 
tolerance of porous alumina implants implanted in 16 eviscerated rabbits; only one infection was 
observed and there was no conjunctival breakdown. Fibrovascular in-growth occurred as soon as 15 
days postoperatively and was full at 1 month. These promising results was confirmed two years 
later by Jordan et al. [143], who compared the performance of alumina and HA implants in rabbits 
again. The authors reported that the new alumina implant was as biocompatible as HA, less 
expensive and its manufacturing did not involve any damage to marine life ecosystems as may 
occur in the harvesting of coral for coralline HA devices. 
A more exhaustive comparison about the proliferation of orbital fibroblasts in vitro after exposure 
to Bioceramic implant and other three implants made of different materials (coralline HA, synthetic 
HA, porous PE) was documented by Mawn et al. [144], who assessed cell growth with 
immunocytochemical analysis using bromodeoxyuridine, a thymidine analogue. The proliferation 
of fibroblasts differed on the various studied implants and, specifically, was maximum on the 
Bioceramic implant. Furthermore, the fibroblasts growing on the Bio-Eye®, synthetic HA and 
Medpor® implants all had debris associated with them, whereas the alumina implant was free of 
these debris, which was mainly attributed to its finely crystalline microstructure. 
Promising results were also published in 2002 by Akichica et al. [145], who implanted pieces of 
alumina with 75 vol.% porosity in the eye sockets of albino rabbits. There were no signs of implant 
rejection or prolapse of the implanted material over a 8-week follow-up; at 4 weeks after 
implantation, fibroblast proliferation and vascular invasion were noted, followed by tissue in-
growth by the 8th week. The first outcomes of Bioceramic implant in humans (107 patients over a 3-
year follow-up) were reported by Jordan et al. in 2003 [146]. Postoperative problems encountered 
with its use were similar to those observed with coralline HA orbital implants (Bio-eye®) but 
appeared to occur rarely; furthermore, the incidence of exposure associated with the Bioceramic 
implant was less than that reported for the HA ones, and infection did not occur in any patient. In a 
following study Jordan and coworkers showed that alumina implant infections are generally rare 
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[147] and, after reviewing a clinical case series of 419 patients who received a Bioceramic orbital 
implant, estimated an implant exposure rate of 9.1% with the majority of the exposures occurring 
after a 3-month follow-up period [148]. Wang et al. [149] reported that exposures of Bioceramic 
implants occurred after long-term follow-up and were preferentially associated with evisceration, 
pegging and prior ocular surgeries, whereas no late side effects were found in enucleated eyes; the 
authors also emphasized that implant wrapping technique can prevent exposure. 
In a recent study, Ramey et al. [128] compared the complication rates of HA, porous PE and 
polyglactin-wrapped alumina implants and, interestingly, found that porous PE and alumina devices 
were associated with higher exposure rates and higher overall complication rates compared to HA 
implants; these results seem to contradict those reported by the majority of authors [147-149]. In 
case of alumina implant exposure, some strategies can be attempted to avoid removal of the implant 
and secondary surgery; for instance, Wang and Lai [150] successfully repaired an exposed 
Bioceramic implant after 4 months after surgery by a retroauricular myoperiosteal graft. This type 
of autologous graft contained myofibrovascularized tissue, provided durable and vascularized 
coverage of exposed implant and only required a nearby harvesting site; the exposure completely 
resolved without recurrence after 2 years of follow-up. Zigiotti et al. [151] recently described a new 
surgical procedure to reduce postoperative complication following alumina implant insertion in 
enucleated eyes. The authors initially performed a standard enucleation on 19 patients; then, they 
covered the Bioceramic implant only partially with the patient’s sclera harvested from the 
enucleated eye, and the implant was finally inserted into the posterior Tenon’s space with the scleral 
covering looking at front. There were no cases of implant extrusion over a 16-month follow-up 
period and the orbital volume was well reintegrated with good cosmetic result after final prosthetic 
fitting (a good motility was also documented). 
 
3.5.7. HA-coated aluminium oxide implants 
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The HA/Al2O3 composite porous orbital implant, developed by a group of Korean researchers in the 
early 2000s, deserves a special mention. A synthetic HA-coated porous alumina implant was 
fabricated by the polymeric sponge replication method in order to overcome the limitations 
associated to coralline HA implants; the porous Al2O3 skeleton acted as a load-bearing member, 
whereas the 20-µm thick HA coating layer was advocated to provide biocompatibility and long-
term stability in the eye [152]. Seong et al. [153] evaluated the morphologic changes of 12-mm 
sized HA/Al2O3 devices with different pore sizes (300, 500 and 800 µm) after implantation in 18 
eviscerated rabbits. Fibrovascularization was noted at the implant periphery in all groups after 2 
postoperative weeks and also at the center of the implant after 4 weeks. Fibrovascularization was 
most predominant in the group of implants having 500-µm pores compared to the other two groups. 
In 2002 Jordan et al. [154] reported a comparative study on the implantation of experimental 
alumina implants coated with HA or calcium metaphosphate in rabbits. Both types of implant had 
multiple interconnected pores and, in comparison to the uncoated one, the coatings increased the 
size of the trabeculae from 150 to 300 µm; therefore, the pores appeared smaller but still ranged in 
the 300-750 µm range. There was no clinical difference in the socket response between coated or 
uncoated implants and, histopathologically, fibrovascularization occurred uniformly throughout 
each implant at 4, 8 and 12 weeks after implantation. 
Three years later Chung et al. [155] investigated the fibrovascular in-growth and fibrovascular 
tissue maturation of HA-coated porous alumina implants in comparison with HA sphere in 
enucleated rabbits over a 24-month follow-up and achieved similar conclusions. There was no 
significant difference between the two groups, except for the 3th to 4th week postoperative period, 
during which the composite sphere showed a significantly lower grade of fibrovascular tissue 
maturation.  
To the best of the authors’ knowledge, no other studies about HA-coated implants have been 
reported in the literature. Although these implants showed similar appearance of 
fibrovascularization, low price and easy manufacture compared to the coralline HA implants (Bio-
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eye®), probably the absence of a clear advantage from a clinical viewpoint (HA coatings did not 
appear to facilitate or inhibit fibrovascular in-growth) and the presence of significant amounts of 
CaO as a contaminant (related to the coating manufacture) [154] led the researchers to abandon 
further investigations. As a suggestion for future research, long-term studies could be useful to more 
clearly determine whether the HA coating actually plays a significant role in the acceptance and 
retention of the implant.  
 
3.5.8. Polyethylene/bioglass composite implants 
 
As first demonstrated by Hench et al. in the early 1970s [156], bioactive glasses (BGs) exhibit the 
unique properties to bond to bone forming a stable interface and to stimulate bone tissue 
regeneration. BGs are recognized as ideal materials for bone substitution with superior 
performances with respect to HA or other calcium-phosphate bioceramics, have been extensively 
investigated over the years in form of dense implants, fine particulate and 3-D porous scaffolds by 
several research groups worldwide [157-163] and some BG-based products are currently available 
on the market [164]. To date, the application of BGs to orbital implants fabrication is quite limited 
and the relevant reports are still scarce [165,166]. 
In 2006, Choi et al. [165] first investigated the in vivo suitability of BG for the manufacture of 
orbital implants; specifically, the authors studied the effects of BG particulate on the fibrovascular 
in-growth that occurred in porous PE orbital implants. Forty-eight rabbits were divided into 4 
equally-sized groups, according to the different surgical techniques and implanted materials used: 
groups 1 and 2 were implanted with porous PE after enucleation or evisceration, respectively 
(reference groups), whereas groups 3 and 4 received porous PE/BG composite implants after 
enucleation or evisceration, respectively. Histological examinations revealed that there was no 
statistically significant difference with regard to fibrovascular in-growth among the 4 groups after 1, 
2, 4 and 8 weeks of postoperative follow-up. Therefore, the authors concluded that inclusion of BG 
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particulate did not significantly promote the rate of fibrovascular in-growth into porous PE orbital 
implants. 
In 2011, Ma et al. [166] reviewed the clinical outcomes of 170 patients after placement of porous 
PE/BG composite orbital implants for primary enucleation or secondary implantation. The majority 
of patients did not experienced any complications (161 cases) and had comfortable socket 
characterized by good implant motility, without conjunctival thinning or inflammation; excessive 
discharge and implant exposure occurred in 2 and 7 cases, respectively. All exposures were 
successfully treated with antibiotics or additional surgery; secondary surgeries were required by 
some patients but not due to implant-related complications (ectropion repair in 5 patients and 
volume augmentation in 3 patients). These early results suggest that the porous PE/BG composite 
orbital implant may be a useful implant for orbital reconstruction, but comparative studies are 
necessary to definitely estimate their performance with respect to the other available – and routinely 
used – implants. 
 
3.5.9. Silicone 
 
In a very recent study, Son et al. [167] compared the extent of fibrovascular in-growth of 
experimental porous silicone orbital implants with that of commercially-available porous PE 
(Medpor®). Both types of spherical implants were implanted in the left socket of 20 New Zealand 
white rabbits after enucleation. At 4 weeks after surgery, porous PE implants showed deeper 
fibrovascular in-growth than porous silicone spheres (42.4% vs. 34.2% of the radius of the 
implants) and a similar trend was also observed after 8 weeks, although the difference was more 
moderate (71.6% vs. 63.6%). This preliminary report demonstrates that porous silicone orbital 
implants exhibit fibrovascular in-growth comparable to that of commercial Medpor® implants and 
might be therefore low-cost, effective alternatives to current porous implants; long-term studies on a 
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larger number of subjects are needed to clearly determine the suitability of porous silicone as an 
orbital implant as well as the advantages/drawbacks ratio. 
 
3.6. Porous quasi-integrated implants 
 
The advantages of porous and quasi-integrated implants, in terms of fibrovascular in-growth and 
motility, respectively, was merged for the first time by Girard and co-workers [168,169] who 
described a porous quasi-integrated enucleation implant made of Proplast II (Vitek, Inc., Houston, 
TX). It differed from Proplast implant I in its composition, being constituted by Teflon and 
alumina, and in having a siliconized non-porous posterior surface to allow smoother movements, 
together with a porous anterior portion to facilitate fibrovascular in-growth. Proplast implant II was 
completely buried maintaining a nipple on its anterior surface that could integrate with a depression 
on the posterior surface of the ocular prosthesis. Several Proplast implants II required subsequent 
removal because of poor motility and, over histopathological examination, were found to be 
completely avascular and surrounded by a pseudocapsule [170]. Use of Proplast II has been still 
reported later as a subperiosteal implant for the correction of anophthalmic enophthalmos in 
patients having poor orbital volume replacement despite the prior insertion of an adequately-sized 
spherical implant within the orbital socket [171]. 
In the same years, Guthoff and associates [172] developed a composite implant constituted by a 
semispherical anterior part made of synthetic porous HA to guarantee tissue integration joined to a 
posterior part that was manufactured using silicone rubber; the horizontal and vertical eye muscles 
were sutured cross-wise in front of the implant to ensure better stability and motility. Overall 
implant biocompatibility was excellent and the transmission of the motility to the prosthesis was 
moderate to good [173,174]. To date this implant is commercialized and considered a good option 
especially in Europe; however, its diffusion is quite limited as standard porous implants seem to be 
generally preferred by surgeons.   
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The more recent evolution of this type of devices is represented by the Medpor QuadTM implant, 
that is conceptually similar to the Iowa implant but fully made of porous PE instead of solid 
PMMA. A preliminary study on 24 patients showed no cases of the “quad” implant extrusion or 
migration; only, 2 patients required deepening of their inferior fornix to accommodate the increased 
motility of their prosthesis [175]. In a following study on 10 enucleated pediatric patients, one case 
of implant exposure was noted with no other significant complications; good motility of the ocular 
prosthesis was reported in all cases [176]. 
 
3.7. Comparison of the present strategies and crucial issues 
 
After presenting in the previous sections an overview of the different types of orbital implants that 
are currently available in the marketplace or have been recently proposed for experimental studies, 
some crucial questions will reasonably raise: first of all, is there a class of orbital implants 
univocally superior to the other ones? And then, more specifically, what is the role of surface 
chemistry and topography of the implant? Are the porous implants truly superior to the other orbital 
implants, including the last generation of PMMA quasi-integrated ones (the Universal implant)? 
Are the clinical outcomes of wrapped implants superior to those of unwrapped ones? Should the 
pegging procedure be clearly recommended to improve the ocular prosthesis motility?   
On the basis of the existing literature, it is almost impossible to give definite responses to this 
complex set of questions; nonetheless, some indications can be presented, together with a series of 
challenges for the future. It is worth underlining once more that, in general, the choice of an 
“optimal” orbital implant is influenced by many factors, including the specific characteristics of the 
injury, cost, the patient’s clinical history and age and the experience/opinion of the surgeon. For the 
reader’s benefit, it is instructive to report part of the results of a recent questionnaire addressed to 
UK ophthalmologists to evaluate current clinical practice in the management of the anophthalmic 
socket [177]. The surgeons’ responses indicated that 55% used porous orbital implants (PE, HA or 
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alumina) as their first choice and 42% used PMMA quasi-integrated implants; most porous implants 
were spherical (diameter 18-20 mm) and only a minority were egg-shaped or conical; 57% wrapped 
the implant after enucleation using salvaged autogenous sclera (20%), donor sclera (28%) and 
synthetic Vicryl or Mersilene mesh (42%); only 7% placed motility pegs in selected cases, usually 
as a secondary procedure; 14% of respondents reported implant exposure for each type of procedure 
and extrusion was reported by 4% after enucleation and 3% after evisceration. In summary, this 
survey highlights that most UK surgeons use porous orbital implants with a synthetic wrap after 
enucleation and only few perform motility pegging. The validity of these results may be reasonably 
extended to the whole European context; however, in other areas of the world, different options 
may be preferred. For instance, as declared by some local surgeons [37], in Pakistan it is quicker 
and less expensive to use the Sahaf quasi-integrated PMMA implant (produced on site) than to 
import porous orbital devices from abroad. 
 
3.7.1. Material features 
 
Looking at the chemical, physical and structural characteristics of orbital implants, comparative 
studies on such topics are actually quite rare in the literature. It has been recognized that adequate 
fibrovascularization is vital for achieving a long-term success of a porous implant: chemical 
composition, microstructure and mechanical features are all factors playing a role, but there is a 
high variation in these characteristics among the available materials. Perhaps the most 
comprehensive study was carried out by Mawn et al. [94], who compared the microstructural and 
architectural features (assessed by SEM) of six porous orbital implants made of HA (coralline Bio-
Eye®, synthetic HA (FCI) and Chinese HA implant), porous PE (Medpor®; two implants with 
nominal pore size of 150 and 400 µm were examined) and alumina (Bioceramic implant). The Bio-
Eye® had multiple interconnected pores in the 300-700 µm range; coarse-appearing 2-µm sized HA 
crystals were also observed. The FCI implant showed similar interconnectivity of the pores but with 
37 
 
fewer pores ranging within 300-500 µm; hexagonal HA crystals (size 1-5 µm) were detected. The 
Chinese HA implant had multiple interconnected pores ranging from 200 to 700 µm in size; the HA 
crystals were a bit smaller and more granular than those of Bio-Eye®. The 150-µm pore size 
Medpor® implant had irregularly-shaped pores in the actual 100-500 µm range, whereas the 400-µm 
pore size implant had channel-like pores actually ranging from 125 to 1000 µm; in both cases the 
surface showed a woven texture of PE. In the alumina implant the pores (size about 500 µm) were 
well interconnected and evenly distributed inside the material volume; the material showed a 
cobblestone-like pattern of crystals ranging from 4 to 5 µm. Therefore, there were marked 
variations of crystal size/shape and surface topography of porous implant biomaterials, and the 
authors suggested that such variations could influence the inflammatory response after implantation 
and hence the overall biocompatibility. From the viewpoint of micro-scale features, crystal size, for 
example, could determine the material-induced phagocytic response: biomaterials with crystal size 
above 3 µm showed greater tissue reaction, which was probably due to increased phagocytic 
activation by crystals of this size. Moreover, smooth HA crystals have been associated with less 
inflammation than sharp-edged crystals [178]. 
In a recent study, Choi et al. [179] examined the surface of non-porous PMMA, porous alumina and 
porous PE intact implants by atomic force microscopy (AFM). The surface of the non-porous 
PMMA implant showed nodule nanostructures in the 160-260 nm range, the alumina implant 
exhibited a porous structure with crystals ranging from 400 nm to 1.1 µm and the porous PE 
implant had the highest roughness with severe surface irregularities. The authors suggested that the 
surface roughness of orbital implants might be associated with the rate of complications and cell 
adhesion. 
From this viewpoint, an important issue to be considered is the effect of micro-/nano-scale 
topography on bacteria, since cells have to compete with bacteria in many environments. In a 
fascinating scenario, surface topography could be purposely designed to encourage cells 
colonization while limiting bacterial adhesion [180]. The currently-available evidences indicate that 
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the relationship between the microstructural features and the clinical performance of orbital 
implants deserves future investigation, which could lead to develop novel design and manufacturing 
strategies. Looking at the macro-scale, pore size and interconnectivity can also influence the 
success of an implant; these features have been shown to be key determinants of tissue in-growth 
into 3-D tissue engineering scaffolds [181]. Rubin et al. [121] studied the vascularization in porous 
HA and PE orbital implants with small and large pore size and suggested that pore size should be 
greater than 150 µm and preferably around 400 µm in order to encourage favourable tissue in-
growth. Another issue deserving investigation concerns the material surface chemistry and response 
to biological fluids through ion-exchange mechanisms, that are expected to play a key role for 
porous implants fibrovascularization; the challenge of the chemical design of orbital implant 
biomaterials, for instance by using BGs [165,166], will be discussed in the section 5.2.1.    
A final interesting issue, which has been almost totally neglected in existing reports, is related to the 
mechanical properties of the implants that, especially if made of ceramic materials (HA, alumina), 
are remarkably stiffer than the original ocular globe as well as the surrounding orbital tissues. The 
use of stiff biomaterials carries some advantages from an operative viewpoint – e.g. the surgeon can 
easily handle and place the implant within the orbit with a great control over its position – but 
compliance mismatch between implant and overlying conjunctiva/soft tissues, in combination with 
repetitive movement of the implant by the extraocular muscles, might contribute to inflammation 
and soft tissue necrosis leading to implant exposure. Therefore, future research directions towards 
an ideal orbital implant might consider the use of more compliant biomaterials; potential options 
might be adapted, for instance, from the field of experimental vitreous substitutes, such as some 
selected hydrogels – biocompatible, porous and able to absorb water for having similar physical 
properties to living tissues [182] – or the capsular artificial vitreous, constituted by a 10-µm thick 
capsule made of a silicone rubber elastomer with a silicone tube valve system filled with 
physiological solution [183]. 
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3.7.2. Motility 
 
From a theoretical viewpoint, one of the major advantages of porous implants (e.g. porous HA, PE, 
alumina) in comparison to the non-integrated ones (e.g. silicone and PMMA sphere) should be the 
improved motility, even without the placement of a peg due to implant fibrovascularization. 
However, to date, no objective difference has been documented in terms of motility associated to 
porous or non-porous spherical implants. In a study on 55 patients, Colen et al. reported no 
statistical difference between the motility of unpegged porous HA and non-integrated PMMA or 
silicone spherical orbital implants (both types were wrapped within a scleral sheet) [184]. 
Analogous conclusions were formulated by Custer et al. in another report involving 107 patients 
receiving sclera-wrapped porous HA or non-integrated spherical implants [185].  
It has been demonstrated that placement of a peg in porous implants may improve horizontal 
excursions [186] but this procedure is associated with some complications including chronic 
discharge, pyogenic granuloma formation, peg extrusion and audible “click” [96] – this is the 
reason why many surgeons and patients generally prefer to avoid peg placement [177]. Peg systems 
are generally designed for peg placement by additional surgery once fibrovascularization of the 
implant has been completed, since drilling into an avascular area may predispose the implant to 
infection [187]; assessment of the extent of implant vascularization can be performed by 
gadolinium-enhanced MRI [122]. Fibrovascular in-growth may occur at varying rates in different 
patients, but implant drilling and peg placement is generally deferred until 5 to 6 months after 
implant insertion. Several titanium peg systems are currently available for use with porous orbital 
implants: for instance, the Medpor® Motility Coupling Post (MCP) (Porex Surgical, USA) is a 
titanium screw that can be screwed directly into porous PE implants [188]. In summary, implant 
pegging seems to improve motility at the expense of a second procedure with related imaging 
studies, postoperative diseases and further costs. In order to overcome these drawbacks, some 
surgeons have experimented the peg insertion at the time of orbital implant placement (Fig. 3e), but 
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this practice still remains controversial [189-192]. Pegging has been sometimes experimented in 
non-integrated silicone spheres with good results [27]. 
A quasi-integrated implant, such as the Universal Implant, can be a valuable alternative to porous 
devices if pegging is not under consideration. From a theoretical viewpoint, the mounded surface of 
quasi-integrated implants should reasonably offer improved motility over a non-integrated sphere as 
a result of the partial coupling that occurs between the mounds on the implant and the posterior 
surface of the ocular prosthesis; however, the report by Smit et al. [193] showed no significant 
difference in prosthesis motility between Allen and sclera-wrapped PMMA baseball primary 
implants (18-mm sphere). 
As far as the authors are aware, to date no motility comparison between quasi-integrated and porous 
orbital implants have been reported in the literature. From these relatively few data from the 
existing literature, it is evident that systematic comparative studies are still needed to draw definite 
conclusions about the superiority of a class of orbital implants over the other ones, at least as far as 
motility is concerned. The quasi-integrated design in a porous form, such as the Medpor QuadTM 
Motility Implant, might at least partially overcome the drawbacks associated to pegging (costs and 
postoperative complications). 
 
3.7.3. Exposure and clinical outcomes 
 
Although comparisons are difficult due to different implant sizes, surgical techniques and follow-up 
periods, there are convincing evidences that the exposures occurring in porous implants are more 
amenable to conservative management without a second operative procedure; on the contrary, the 
exposures in non-integrated and quasi-integrated implants, unless very limited, almost certainly 
require implant removal [15,194]. Implant wrapping is useful to decrease the risk of exposure, since 
the smooth wrapping material acts as a barrier between the overlying soft tissue and the micro-
/macro-rough surface of the implant, which is particularly helpful in the case of HA implants having 
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a rougher surface than other implants [91,100]. It has been demonstrated that the rough surface of 
unwrapped HA implants appears to be associated with a higher exposure rate when compared to 
non-integrated implants, and also sclera-covered HA implants seem to have higher late exposure 
rates than sclera-covered non-porous silicone implants [91,100] – but the former ones can be more 
successfully treated. Exposure rates for porous PE implants wrapped in absorbable material were 
found similar to those of unwrapped porous PE [117].  
From a general viewpoint, implant wrapping carries some additional advantages as it enables easy 
attachment of extraocular muscles for better prosthesis motility, entails a smooth external surface 
thus making the process of implant insertion easier and helps volume augmentation by adding 1 to 
1.5 mm of material to the implant diameter. Human donor sclera is the most commonly used 
wrapping material, but specially-processed bovine pericardium, human fascia lata and acellular 
dermis are also commercially available. Especially in the past, allografts and xenografts were 
associated to the risk of disease transmission from donor to patient, such as human 
immunodeficiency virus (HIV), hepatitis B or C and prions (Creutzfeldt-Jakob disease). Currently, 
at least in Europe and USA, extensive legislation exists and the donor sources are carefully checked 
before a graft is released for clinical use. Autologous sclera can also be used if enucleation is 
performed but its use must be avoided in case of ocular tumour. Alternative autografts include 
temporalis fascia, fascia lata, rectus abdominus sheath and posterior auricular muscle complex 
grafts, but the use of these tissues requires a second operative site, extra-surgery time and carries the 
risk of morbidity at the harvesting site; therefore, synthetic wrapping materials such as polyglactin-
910 mesh are often preferred [8,9]. If non-absorbable wrapping material is used, the surgeon should 
consider the creation of holes through the wrap to allow a good vascularization of the porous 
implant. 
In summary, it appears that the incidence of implant extrusion and socket infection is lower with 
porous implants; this supports the theoretical considerations that vascular in-growth helps to anchor 
the implant and permits immune surveillance. In case of implant exposure, implant savage by the 
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placement of frontal patches represents a successful approach [105]. Therefore, from the viewpoint 
of exposure-related complications porous implants seem to be preferable to other implant types, at 
least when surgery is performed in adults. When eye removal is performed in infancy, implant 
exchange may be necessary to stimulate adequate orbital growth; therefore, the use of porous 
implants in children is controversial, since implant exchange is more difficult once a porous implant 
has been vascularized.  
By looking at the commercially-available porous orbital implants, it is impossible to univocally 
claim one porous material as clearly superior to the others, even though alumina, exhibiting 
excellent biocompatibility and favorable microstructural features [94], seems a promising candidate. 
The search for “ideal” orbital implant design and materials continues to progress due to significant 
improvements in analytical techniques for materials/implants analysis and patient monitoring. A 
robust comparison of currently-available orbital implants, as well as the clear detection of what 
features might be selectively improved, is difficult due to the relative scarcity of large randomized 
controlled trials in this area, the significant variations in patient populations, the differences in 
surgical technique, the wrapping option and the length of follow-up, as complications may not be 
apparent until 5 or more years post-operatively [44]. The results of well-designed, longer-term 
studies on the orbital implants performance could contribute to clarify some of these issues in the 
next years. 
 
4. Ocular prostheses 
 
Over the centuries, different models of ocular prostheses were tested and described, including metal 
(usually gold) shells with the iris painted in coloured enamel and thin, fragile glass shells that often 
had poor fit and little comfort [16]. Generally, all these prostheses were not supported by an orbital 
implant placed in the socket (there was no volume replacement), which was clearly reported by 
Mules only in 1885 [2]. At the end of 19th century, a thick but hollow glass artificial eye (the so-
43 
 
called Snellen reform eye), that better compensated for volume loss after enucleation and reduced 
the sunken appearance of post-enucleation prostheses, was introduced and remained the standard 
until WWII [16]. Since the 1940s, the introduction of PMMA revolutionized the field of both 
orbital implants and ocular prostheses [18].  
 
4.1. Post-surgical conformers 
 
A final artificial eye (ocular prosthesis) is manufactured as soon as the postoperative inflammation 
has settled, usually within 6-12 weeks after surgery. During this time, a temporary acrylic 
conformer, commonly made of PMMA, is worn to keep the fornices formed and to prevent socket 
contracture [195,196]. Two holes are usually present in the conformer to allow the drainage of 
discharge from the socket and to make easier the application of medication (e.g. therapeutic drops) 
[196]. Standard conformers do not resemble a natural eye and often do not fit very well the correct 
ocular dimensions – they are too large or too small. Low-cost, pink acrylic resin for dentistry is 
often employed to make postoperative standard conformers. 
Cosmetic conformers, exhibiting a variety of sizes, iris colours and scleral colours, are also 
available to patients. While they do not provide as good a fit or cosmetic appearance as the custom-
made ocular prosthesis, however they are a valuable temporary option. A study published by Patil et 
al. showed that the majority of patients was pleased to wear a cosmetic conformer instead of a 
standard conformer, although the latter was less expensive [197]; the authors also highlighted that 
this early cosmetic improvement seemed to be very important in the emotional rehabilitation of 
patients following the loss of an eye. 
 
4.2. Definitive ocular prostheses 
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The ocular prosthesis, as previously mentioned, fits over the orbital implant – with or without 
coupling by a peg – and sits just behind the eyelids. Professional ocularists are responsible for the 
overall fabrication and fitting of ocular prostheses (creation of the impression, shaping and painting 
the prosthesis); they also have to instruct the patient on how to place and care for the prosthesis, 
providing long-term support and help.  
From a historical standpoint, before the WWII the majority of ocular prostheses were made of glass 
– hence they were popularly referred to as “glass eyes”; however, artificial glass eyes were brittle 
and prone to implosion with acute changes in temperature, as already discussed about the Mules 
orbital implant [2]. Furthermore, over time the glass prosthesis became etched from exposure to 
body secretions and usually lasts only about 2 years [197]. The battles of WWII created a large 
demand for artificial glass eyes, that were mainly produced in Germany; the unavoidable wartime 
shortage of ocular prostheses imported from this country led to the development, especially in the 
USA, of a new generation of artificial eyes based on acrylic resin. Interestingly, the introduction of 
PMMA ocular prostheses mirrored the advances of orbital implants, as the early models of quasi-
integrated and mechanically-integrated PMMA orbital implants were also proposed in the mid 
1940s. 
Today, most of available prostheses are either stock or custom-made PMMA devices. With respect 
to glass, PMMA is more durable and has a longer life expectancy as well as better tissue 
compatibility [197]; however, glass is still used in selected cases. Stock, or ready-made, prostheses 
are advantageous when time and cost are limited because they can be fabricated rapidly with acrylic 
materials found in any dental office; furthermore, they do not require an artist to complete the 
painting of the iris and the sclera. However, stock prostheses are available in a limited range of 
sizes and iris colours. The size limitation is a concern because an improperly-fitting prosthesis may 
not only distort the lid and socket but it could also create an air pocket between the prosthesis and 
the socket, which provides a good medium for bacterial overgrowth. Moreover, rough fitting of the 
prosthesis may leave pockets where fluids stagnate; as a result, trapped fluid may gush forward in 
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response to firm eyelid closure – which is a socially unpleasing situation. The colour limitation of 
stock prostheses is also a concern for many patients because the iris colour of the prosthesis is often 
noticeably different from that of the healthy eye, which is aesthetically displeasing.  
The preferred ocular prostheses are then the custom-made PMMA prostheses, fabricated through a 
multi-step processing schedule. To ensure that the artificial eye sits in a natural position and does 
not fall back into the socket and to minimise any space in which infected debris could collect, the 
device should be shaped to match the contours of the orbital tissues. Therefore, an impression of the 
socket is taken using a quick-setting material such as dental alginate; once set, the alginate is 
removed and a plaster of Paris mould is made from it. The mould is used to cast a wax shape, which 
is then trimmed to fit the socket. A further mould is made from the modified wax shape, and the 
PMMA prosthesis is finally cast in this mould. A hand-painted iris button is placed on the front of 
the eye, scleral features (e.g. veins) are painted on and clear plastic is laminated over the top (Fig. 
4). Of course, the prosthesis should be tested in the patient’s eye during the manufacturing process 
for proper fit and aesthetic appearance: symmetry of the iris in the palpebral opening and the 
alignment and plane of the irises in both the artificial and healthy eye are determined with the use of 
a corneal-iris button. Correct position of the iris is also ensured by measuring the distance from the 
facial midline and pupillary light reflex in the healthy eye and duplicating this measurement for the 
prosthesis.    
The use of silicone as an alternative for the manufacture of ocular prostheses has been alternatively 
advocated or castigated over the years, and this controversy still lingers on. Since the mid 2000s, a 
silicone ocular prosthesis together with the so-called “Flexiglass system” – a kit for making the 
prosthesis – has begun to be marketed in the USA by the same producer. On the product website 
[31], silicone was claimed superior to PMMA as the latter was considered responsible of adverse 
reactions in certain patients and due to the toxicity of the catalyst used for PMMA production; it is 
textually reported that “the Flexiglass™ System is also now available globally. All of the products 
in the system comply with the medical device directives for a class 1 customizable medical device 
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and are CE compliant”. However, as far as the authors are aware, the USA Society of Ocularists 
maintain the position that the quality of silicone prostheses is poor compared to that of acrylic-
based ones, and therefore PMMA still remains the material of choice for the majority of ocularists, 
ophthalmologists and patients. Serious, comparative studies would be useful to give ultimate 
conclusions and full clarification to this issue. 
The patients should receive precise instructions regarding the proper care and use of their own 
ocular prosthesis. It is strongly recommended to wear eye prostheses overnight during periods of 
orbital growth, and they may be worn overnight even later especially to prevent eyelashes turning in 
and irritating the conjunctival surface; however, if conjunctival inflammation develops, it is better 
not to wear the prosthesis during sleep. Cleaning can be performed by hand with a simple liquid 
surfactant; the ocular prosthesis should be then dried at air as paper tissues or towels could scratch 
the surface or allow bacterial contamination. Bacterial colonization of the posterior surface of the 
artificial eye in contact with the patient’s conjunctiva or with the orbital implant’s peg could be a 
crucial issue during the follow-up and lead to the development of infections; interesting strategies to 
overcome this problem are discussed in the section 5.2.3. 
 
4.3. Cosmetic contact lenses 
 
The removal of an eye is an extreme surgical option and not all painfully disfigured, atrophic, often 
blind ocular globes undergo such a fate; in many cases, pharmaceutical treatments can be 
administered to reduce pain and cosmetic solutions alternative to surgery are explored. Cosmetic 
contact lenses can be considered, at least to some extent, a particular subset of ocular prostheses and 
are intended to disguise eyes with unacceptable appearances; the lenses fall into three groups, i.e. 
scleral shells, soft corneoscleral contact lenses and rigid corneal contact lenses.  
PMMA scleral shells are indicated when a blind eye is shrunken or its surface is very uneven; the 
thickness of the shell can be varied to properly fill out the volume deficit that accompanies ocular 
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atrophy. Scleral shells should be worn only while awake as the shell occludes the cornea, placing it 
under metabolic stress and thereby increasing the risk of ulceration; even more scrupulous care 
should be taken over the maintenance and cleaning (by an appropriate surfactant) of a scleral shell 
than over a whole eye prosthesis, behind which a “living” ocular globe does no longer exist.  
Soft corneoscleral lenses are made of different types of hydrogels and can be recommended to hide 
corneal scars (due to trauma or infections) and iris defects (due to trauma or congenital diseases) in 
normal sized eyes that have a fairly regular surface. Soft lenses cannot be used if the eye is so 
misshaped that the lens will not centre or if the tear film is deficient. These lenses can be fully 
occlusive, with both pupil and iris coloured to match the fellow eye, or can have a clear pupil if the 
eye is sighted. Soft lenses should be worn only while awake for the same reasons that apply to 
scleral shells. 
Rigid lenses are made of PMMA and their fabrication process and external features are analogous 
to those of definitive ocular prostheses.  
 
5. Future perspectives and research challenges 
 
5.1. The potential of advanced imaging techniques 
 
Periodic monitoring of composition, density, volume and shape changes of orbital implants in vivo 
is essential to gain key information about the postoperative outcomes; in particular, the assessment 
of fibrovascular in-growth is extremely important when porous implants are used. Over the years, 
several imaging techniques have been developed and are currently at the surgeons’ disposal. 
Medical source CT (MSCT) scanning has been widely used [121,198,199] but has the disadvantage 
of a significant radiation dose with each examination. Other imaging options to verify implant 
vascularization include gadolinium-enhanced MRI [122,200-202] and technetium 99m bone 
scintigraphy [203-205]. 
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Intraorbital implant examination with cone beam CT (CBCT), having lower radiation exposure than 
MSCT, may be a simpler, less expensive and reliable alternative for the detection of soft and hard 
tissues which still has to be fully evaluated. CBCT was first described in the early 1980s and since 
then applied to dentomaxillofacial diagnostics [206,207]. In the past CBCT was less accurate than 
MSCT in tissue density measurements, but recent advances allowed to achieve a voxel resolution 
from 400 to 70 µm, whereas MSCT voxels are generally larger than 250 µm. However, image noise 
is generally higher with CBCT [208], while the dose of radiation is much lower [206].  
In a recent work, Lukats et al. [209] highlighted the potential of CBCT in tissue engineering 
applications wherein long-term monitoring of scaffolds in a noninvasive manner with the lowest 
possible doses of radiation is required, and applied this technique to evaluate 30 enucleated patients 
receiving polyglactin-wrapped HA and alumina orbital implants over a mean follow-up of 3.2 
years. Implant volume, orientation and shape estimations were possible while density evaluation 
was more complicated compared to MSCT and required careful calibration procedures. This 
approach is interesting and would deserve further investigations in next years to achieve definite 
conclusions about CBCT suitability in the ophthalmoplastic field. 
As a final remark, it is worth mentioning that advanced imaging techniques associated to 
CAD/CAM systems for implant prototyping could disclose a great potential to fabricate ever more 
accurate, custom-made implants able to successfully fulfill the patient’s anatomic and cosmetic 
needs; this issue will be further discussed in the section 5.2.1.    
 
5.2. Smart biomaterials and implants with advanced and multipurpose properties 
 
5.2.1. Bioactive glass-based orbital implants 
 
BGs have been commercialized worldwide for almost 30 years mainly for bone defect and dental 
repair [164]. In the specific context of oculo-orbital surgery, BGs have been implanted in humans as 
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small plates for orbital floor repair [5,210-212] and introduced as particulate in experimental PE/BG 
composite porous orbital implants [165,166]; moreover, Lloyd and associates recently proposed the 
use of porous BG as an osteo-odonto-keratoprosthetic skirt material [213]. Hence, there are 
increasing evidences that BGs could have a great potential also for ophthalmic applications and the 
authors wish to report here some remarks to emphasize their possible impact in the development of 
a new generation of orbital implants with advanced properties that only few years ago would have 
seemed impossible.  
BGs have not only the ability to bond to bone [156], but they were also found to stimulate new bone 
growth and to bond to soft tissues in vivo [159]. It was observed that ionic dissolution products 
from BGs play a key role in affecting the biological response of such materials in vitro and in vivo, 
stimulating the expression of several genes of osteoblastic cells towards a path of regeneration and 
self-repair [214]. Since many trace elements (e.g. Sr, Cu, Zn) present in the human body are known 
for their anabolic effects in bone metabolism, a new approach for enhancing the bioactivity of BG 
and BG-derived products could imply the introduction of therapeutic ions into the BG formulation. 
The subsequent release of these ions after exposure to a physiological environment is believed to 
exhibit possible antibacterial [215] or anti-inflammatory [216] effects and to selectively affect the 
response of human cells towards angiogenesis [217,218]. As to the type of orbital implant that 
might be fabricated by using BGs, porous spherical devices (scaffolds) conceptually similar to those 
made of HA or alumina would seem the most likely candidates; clearly, cell response will depend 
not only on chemical composition, but also on surface micro-/nano-roughness, porosity, 
topography, grain size and crystallinity (if a final glass-ceramic material will be obtained) of the 
implant [180,218]. 
Considering the particular application, it is worth pointing out an important aspect: osteogenesis 
stimulation and bone-bonding ability seem not to be desirable features for an orbital implant, but the 
added values to be pursued are the enhanced angiogenesis and fibrovascularization that may be 
induced by BGs. In fact, it has been recognized that vascularization is a desirable characteristic of 
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orbital implants since it discourages bacterial colonization of the surface and permits treatment of 
low-grade ocular infection with systemic antibiotics. Hence, an accurate design of BG composition 
should be performed to synthesize materials suitable to stimulate angiogenesis and 
fibrovascularization without inducing bone cells recruitment and bone in-growth. Furthermore, the 
dose effect also seems to play a key role: in a recent study, it has been observed that BG exhibits 
proangiogenic potential at low concentrations and significant osteogenic potential at higher 
concentrations [219]. It was reported that the BG surface reactivity, which is so critical in bone 
adhesion, does not imply a toxic effect in non-osseous tissues [220] and BGs were shown to be able 
to bond also to soft tissues [159,164].   
A detailed overview of the studies investigating the BG effect on angiogenesis in vitro has been 
recently reported by Gorustovich et al. [221]. From a general viewpoint, in vitro experiments have 
shown that BGs stimulate the secretion of angiogenic growth factors in fibroblasts, the proliferation 
of endothelial cells and the formation of endothelial tubules [217,222]. Day et al. [217] found that 
L929 fibroblasts cultured on the surface of poly(L-lactic-co-glycolic acid) (PLGA)/Bioglass® discs 
with 0.01%, 0.1%, and 1% (w/v) of 45S5 Bioglass® particles (size < 5 µm) secreted increased 
amounts of vascular endothelial growth factor (VEGF) compared with cells cultured on PLGA 
alone. Keshaw et al. [222] recently reported that microporous spheres of PLGA containing 10 wt.% 
of 45S5 Bioglass® particles (mean particle size = 4 µm) stimulated a significant increase in VEGF 
secretion from CCD-18Co fibroblasts consistently over a 10-day period compared with neat PLGA 
microporous spheres.  
In vivo results have confirmed that BG is able to stimulate and to promote neo-vascularization, as 
highlighted by Gerhardt and Boccaccini in a recent review [223]. Leu and Leach [219] filled 
calvarial defects in Sprague-Dawley rats with 45S5 Bioglass®-impregnated collagen sponges, using 
unloaded empty sponges as a control; after 2 weeks of implantation, histological analyses of 
calvaria demonstrated significantly greater neo-vascularisation and vascular density within the 
defects treated with the BG/collagen composite sponges as compared to collagen controls alone. In 
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a recent study, Gerhardt et al. [224] investigated the angiogenic potential of poly(D,L-lactide) 
(PDLLA)/45S5 Bioglass® porous composites wherein micro-sized and nano-sized BG particles 
were used. The authors observed that human fibroblasts produced 5 times higher VEGF if cultured 
on BG-containing (20 wt.%) composite in comparison to pure PDLLA; furthermore, after 8 weeks 
of implantation in Sprague-Dawley rats the composites were well-infiltrated with newly formed 
tissue and demonstrated higher vascularization and blood vessel-to-tissue percentage (11.6-15.1 %) 
than PDLLA scaffolds (8.5%). Following an interesting approach, Vargas et al. [225] used the quail 
chorioallantoic membrane as an in vivo model to evaluate angiogenesis and observed that addition 
of 10 wt.% of silicate BG nanoparticles to collagen films induced an early angiogenic response, 
which makes these composites promising matrices for tissue engineering and regenerative 
medicine.  
Apart from the advantages from a biological viewpoint, BGs also have other attractive properties. 
BGs are very versatile as they are synthesizable in form of powders, granules or 3-D porous 
scaffolds of various size and shape including the spherical one typical of orbital implants (Fig. 5a). 
Macroporous scaffolds can be obtained by a variety of methods such as foaming techniques [226], 
organic phase burning-out [227] and sponge replication [157,161]. If glasses are processed in form 
of mesoporous materials (Fig. 5b), they can also easily incorporate specific molecules, for instance 
anti-inflammatory drugs, to be released in situ postoperatively to elicit an appropriate therapeutic 
effect [228-230]. Custom-made BG-derived porous orbital implants could be fabricated by using 
rapid prototyping techniques [231]: CT- and MRI-derived files can act as input data for CAD/CAM 
manufacturing systems in order to produce scaffolds matching exactly the dimensional features of 
the anophtahlmic socket. Recent studies have demonstrated that advanced manufacturing 
techniques such as lithography-based methods [232] or selective laser sintering [233] can lead to the 
production of high-quality porous scaffolds of complex shape with an accurate control of pore size 
and interconnectivity. Furthermore, BG-derived products can be easily, quickly and effectively 
sterilized, for instance by β- or γ-irradiation, without undergoing degradation.  
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Specific added values can be imparted to BG-derived products by appropriate surface treatments 
[163]: for instance, use of silver-doped glasses [234] to produce orbital implants exerting 
antibacterial properties could be a promising strategy for the future (an example of silver-doped 
layer on the surface of a bioactive glass, obtained by ion exchange, is reported in Fig. 5c); this topic 
will be treated in more detail in the section 5.2.3.  
A further opportunity to improve the biological performances of bioactive glasses involves their 
surface functionalization. Silica-based glasses easily expose reactive hydroxyls groups on their 
surface by simple water treatments, and these functionalities can be employed for the grafting of 
appropriate biomolecules/drugs eliciting specific responses/therapeutic actions. For instance, Verné 
and associates successfully coupled biomolecules and drugs to different bioactive glasses and glass-
ceramics for bone regeneration and cancer treatment [235,236]. In this way, the idea of grafting 
specific growth factors to enhance vascularization, or drugs to reduce inflammation and infection, 
could be of interest also in the field of orbital implants. 
Comprehensive reviews dealing with the recent advances on bioactive porous glasses and glass-
ceramics have been published in last years and are available to interested readers [163,223,237].  
In the light of the above-discussed properties of BGs, in the next future a 8th type of orbital implant 
could be included in Table 2, as BG-based porous implants are expected to fall under the definition 
of “bioactive orbital implants”. In biomaterials science and regenerative medicine, the term 
“bioactivity” refers to the ability of a biomaterial to perform a desired, appropriate function 
generating the most appropriate beneficial cellular or tissue response in a specific situation. Of 
course, bioactivity implies biocompatibility (that is a sort of pre-condition), i.e. the ability of a 
biomaterial to perform its function without eliciting any undesirable local or systemic effects in the 
recipient, according the definition provided by Williams [238]. In the context of anophtalmic 
surgery, as previously mentioned one of the most important functions to be performed by the 
(porous) orbital implant biomaterial is the promotion of fibrovascularization, which could be 
actually enhanced by in situ release from a BG implant of suitable metal ions eliciting an 
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angiogenetic effect [218]. The possibility of making porous orbital implants fully constituted by 
BGs was disclosed by Richter et al. in a recent patent [239] but, as far as the authors are aware, no 
manufacturing or clinical studies have been reported yet in the literature on this type of implants; 
early studies on BG/PE composite orbital implants have been carried out [165,166] but further 
investigations are needed to obtain more substantial conclusions.   
Few closing remarks on the concept of orbital implant bioactivity need to be presented. In this 
work, BG-based orbital implants are defined “bioactive” as BGs were shown to intrinsically exert 
an active role, mainly by the deliberate release of appropriate ions, in stimulating and directing 
angiogenesis at the cellular and genetic level; therefore, the term “bioactive” is equivalent to 
“angio-inductive”. On the other hand, fibrovascular in-growth has been observed also in 
commercially-available HA, PE and alumina orbital implants from which no release of “angio-
stimulating” ionic species occurs. In these cases, however, the vascular in-growth is possible due to 
the presence of a 3-D porous network in the implants; therefore, these porous biomaterials should 
be defined “angio-conductive” instead of “angio-inductive” (i.e. “bioactive” in a strict sense). 
Alternatively, adopting a remarkable simplification and focusing the attention only on the final 
effect (i.e. the fibrovascular in-growth inside the implant), all porous orbital implants might be 
defined as potentially “bioactive”, but in this way the peculiar, intrinsic features of the different 
biomaterials would be no longer taken in account.   
 
5.2.2. Absorbable orbital implants 
 
All orbital implants developed over the years have been designed to be permanent, i.e. they should 
remain in situ indefinitely during the patient’s whole life without undergoing resorption, 
degradation or partial/total replacement by surrounding tissues. An interesting exception has been 
proposed in a patent deposited in the late 1990s by Durette [240], who disclosed an approach in 
partial countertendency with respect to the established perspective. The Durette orbital implant was 
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provided with a passageway extending from the anterior surface inwardly to receive a peg prior to 
implantation; the peg should be made of non-porous material so that the surrounding tissue would 
encapsulate it without a tight contact. A cap of absorbable biomaterial was placed in front of the 
implant in order to create a “cushion” between implant and overlying ocular prosthesis, that would 
be later coupled to the implant by means of the peg without the need for a second drilling procedure 
for peg placement. Durette specified that the implant should be preferably made of biodegradable 
material having a matrix with random voids throughout to enhance tissue in-growth [240].    
The ideas suggested by Durette are fascinating and would deserve careful experimentation in the 
next years. A partially absorbable implant able to increase its porosity in vivo, thereby allowing 
improved fibrovascularization, could represent a clever approach; however, the use of a fully 
biodegradable orbital implant poses several issues, especially concerning the kinetics of socket 
volume replacement by tissue during implant degradation and the ocular prosthesis motility in 
absence of an implant that can transfer movement to it.   
 
5.2.3. Antibacterial devices 
 
Bacterial issues in ophthalmic applications, with particular reference to postoperative infection of 
ocular implants, can cause significant problems followed by post-surgery additional treatments that 
are both expensive and stressful for patients [104,106,125,126,147,241-242]. Over the years, some 
strategies have been experimented to limit the risk of bacterial colonization at the time of surgery; 
for instance, it is a common practice to impregnate porous HA orbital implants in antibiotics prior 
to implantation in the orbital socket [244]. This approach is certainly useful intraoperatively, but a 
key challenge of modern ophthalmology is to develop smart biomaterials able to exert a long-term 
antibacterial activity in order to limit late bacterial colonization and infection of the implant. 
Moreover, the widespread and increasing use of antibiotics led to the development of antibiotic-
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resistant bacteria and, therefore, there is the need for investigating alternative strategies and 
approaches.  
Attempts at imparting intrinsic antiseptic properties to the devices for ophthalmoplasty (ocular 
prosthesis and orbital implant) are very rare in the literature. In a recent patent, Jun et al. disclosed 
an antibacterial ocular prosthesis produced by incorporating small amounts of silver, gold or 
platinum nanoparticles in the acrylic resin (PMMA) or silicone used to fabricate the prosthesis; the 
patent also related to a conformer produced by the same method and having antibacterial properties 
in itself [245]. Following a similar approach, Yang et al. produced a PMMA-based ocular prosthesis 
dispersing silver nanoparticles in the resin (concentration from 300 to 700 ppm), tested its 
antibacterial properties in vitro against Streptococcus pneumoniae, Staphylococcus aureus, 
Pseudomonas aeruginosa and Escherichia coli and reported that the antimicrobial activity of the 
Ag-containing artificial eye was 4.8-6.2 times stronger than that of controls [246]. Both approaches, 
however, pose some problems associated to the release of nano-sized silver, which could be a 
crucial issue for the implant applicability since tissue toxicity of metal nanoparticles has been 
reported in several in vitro and in vivo studies [247,248]. 
A promising strategy, that was very recently proposed in a patent by the authors [249], involves the 
deposition of an antibacterial composite coating on the surface of ocular prostheses and orbital 
implants. The coating is preferentially constituted by silver nanoclusters embedded in a silica matrix 
and can be produced by radio-frequency (RF) co-sputtering of silver and silica used as targets (an 
example of TEM cross-sectional image is reported in Fig. 5d). Previous papers demonstrated that 
these coating can be successfully deposited on wide variety of substrates (e.g. silicate glasses, 
polymers) and are able to retain their mechanical stability and antibacterial characteristics even after 
heating above 500 °C [250-252]. Other matrices (e.g. alumina, TiO2, polymers) and antibacterial 
metal agents (e.g. copper, zinc) may be experimented to find the best solution depending on the 
type of substrate material to be coated and on the biological environment wherein the antibacterial 
device will exert its function. The proposed coatings are generally thin (from few tens to thousands 
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of nanometers) in order to maintain bulk properties of substrates and, in particular, possible 
flexibility of polymeric materials. 
The co-sputtering technique has the advantage to allow the tuning of the antibacterial metal 
concentration through the control of the deposition parameters (e.g. power, pressure in the 
deposition chamber) and the metal nanoclusters size by using thermal treatment following the 
sputtering process [250]. In such a way, in a fascinating scenario it would be possible to tailor and 
to properly design the antibacterial effect in terms of both efficacy (amount of released antibacterial 
agent) and persistency (more or less prolonged kinetics of release). Considering the silver/silica 
composite coatings produced by this method in preliminary studies, it has been observed that the as-
sputtered coatings contained small silver nanoclusters (diameter of 5-10 nm) that increased their 
size by heating up to 600 °C [250]. Moreover, it has been also demonstrated by leaching test in 
different conditions (water or simulated body fluid at 37 °C) that the obtained coatings were able to 
exert an antibacterial activity for at least 1 month [250]. Furthermore, there are preliminary 
evidences suggesting that silver is released in ionic form instead of nanoparticles: this is a 
significant added value overcoming the toxicity issues related to metal nanoparticles delivery. 
Moreover, the use of metals as antibacterial agents instead of antibiotics, commonly employed in 
therapy and prevention of implant-related infections, could overcome the problem of bacterial 
resistance and can be effective also on resistant bacterial strains. 
In the case of ceramic orbital implants, such as the HA or alumina ones, ion exchange techniques 
for surface silver-doping are also suggested in the patent [249], on the basis of the good results 
obtained with surface treatment of glass and glass-ceramic substrates (Fig. 5c) [234,253].  
Exploitation of appropriate metal ions release from biomaterials surfaces for antiseptic purposes is 
certainly a valuable and promising strategy, and not only in the ophthalmic field [218]. However, it 
cannot be ignored that ocular environment is particularly complex and several parameters should be 
taken in account for designing really suitable implants; for instance, the interaction of metal ions 
with the tears, the fate of released ions and the possible ion-induced eye tissue necrosis are all 
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aspects deserving careful consideration. Being such topics very new, the existing literature is very 
scarce but it is instructive to mention a significant case recently documented by Hau and Tuft [254], 
who described corneal argyrosis associated with silver nitrate-coated cosmetic soft contact lenses 
that a 67-year-old woman wore for 17 years for the management of intractable diplopia: this is a 
typical example of an apparently unexpected side effect detectable only after many years of follow-
up. In the next years an ever increasing cooperation among materials scientists, chemists, biologists, 
oculo-orbital surgeons, ocularists and researchers in the medical implant industry would be 
desirable in an attempt to select and market more suitable and cost-effective biomaterials for the 
management of the anophtalmic socket, in order to further improve the patient’s quality of life.  
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Figure legends 
 
Fig. 1. Sagittal sections of a human orbit after enucleation surgery followed by placement of a 
spherical implant that replaces the volume deficit created by eye removal. In these pictures, the 
extraocular muscles are sutured directly to the implant. The ocular prosthesis is designed to fit in 
between the eyelids and the conjunctiva/implant in order to mimic the normal appearance of a 
healthy eye. The connection between orbital implant and ocular prosthesis can be indirect, due to 
the interposition of the conjunctiva (a), or direct, by the use of a peg (b). Pegging procedures are 
normally performed only in porous orbital implants. After some months from primary surgery, a 
hole can be drilled into the anterior section of the implant; a peg is then inserted in the hole. Use of 
pegged implants leads to a greater transmission of movement of the implant to the artificial eye, 
giving a more life-like appearance. 
  
Fig. 2. Use of PMMA for manufacturing orbital implants: (a) pear-shaped implant (Sahaf implant 
type I) (image adapted from Kamal et al. [38]); (b) comparison between the Iowa implant (upward) 
and the Universal implant (downward), showing that the latter has softer mounds in comparison to 
the Iowa predecessor (image adapted from Sami et al. [15] © Elsevier); (c) magnetic orbital implant 
and (d) associated ocular prosthesis exhibiting magnet rusting in both components, which may 
induce late exposures over the central surface of the implant associated to tissue necrosis due likely 
to iron toxicity (images adapted from Sami et al. [15] © Elsevier).  
 
Fig. 3. Porous orbital implants: (a) coralline HA sphere (Bio-eye®); (b) some examples of porous 
PE implants (Medpor® line): simple sphere, conical, egg-shaped, “quad” motility implants (courtesy 
of Porex Surgical); (c) SEM micrograph showing the porous structure of an alumina implant 
(Bioceramic implant) (image adapted from Jordan and Klapper [23] © Springer); (d) HA spherical 
implant wrapped within polyglactine 910 mesh prior to surgery (image adapted from Lukats et al. 
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[209]); (e) vicryl mesh-wrapped HA orbital implant with a titanium sleeve placed before surgery 
(primary placement) (image adapted from Liao et al. [192] © Nature Publishing Group).   
 
Fig. 4. Typical PMMA ocular prosthesis: (a) hand painting of the iris button, so that it can be as 
similar as possible to the aesthetic appearance of the healthy eye (b); (c) frontal appearance (with 
painted capillary vessels) of the final prosthesis after polishing for optimal fit to the patient’s 
anatomy; (b) posterior convex surface. 
 
Fig. 5. Smart biomaterials and strategies for the possible development of future orbital implants 
with advanced properties: (a) SEM micrograph showing the porous structure of a bioactive SiO2-
based glass scaffold fabricated by sponge replication method: its 3-D interconnected pore network 
is similar to that of Bioceramic implant (Fig. 3c); (b) TEM image showing the ordered mesoporous 
structure (parallel channels with diameter of about 5 nm) of a mesoporous bioactive glass (ternary 
system SiO2-CaO-P2O5) wherein therapeutic agents, drugs or suitable organic moieties could be 
incorporated for subsequent controlled release in situ; (c) silver diffusion profile (the surface is on 
the left) on the cross-section of a silver-doped glass (ternary system SiO2-CaO-Na2O) estimated by 
compositional analysis (EDS) (image adapted from Verné et al. [234] © Elsevier); (d) high-
resolution TEM image showing the cross-section of a silver nanocluster/silica composite thin 
coating deposited on silica substrates by radio-frequency co-sputtering (image adapted from 
Ferraris et al. [250] © Elsevier). The approaches illustrated in (c) and (d) are potentially useful to 
impart antiseptic properties to the orbital implant material [249]. 
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